<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d2 20140930//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Genomics</journal-id><journal-id journal-id-type="iso-abbrev">BMC Genomics</journal-id><journal-title-group><journal-title>BMC Genomics</journal-title></journal-title-group><issn pub-type="epub">1471-2164</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4289354</article-id><article-id pub-id-type="pmid">25412710</article-id><article-id pub-id-type="publisher-id">6829</article-id><article-id pub-id-type="doi">10.1186/1471-2164-15-1008</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Fumagalli</surname><given-names>Debora</given-names></name><address><email>debora.fumagalli@bordet.be</email></address><xref ref-type="aff" rid="Aff10"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Blanchet-Cohen</surname><given-names>Alexis</given-names></name><address><email>Alexis.Blanchet-Cohen@ircm.qc.ca</email></address><xref ref-type="aff" rid="Aff11"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Brown</surname><given-names>David</given-names></name><address><email>david.brown@bordet.be</email></address><xref ref-type="aff" rid="Aff10"/></contrib><contrib contrib-type="author"><name><surname>Desmedt</surname><given-names>Christine</given-names></name><address><email>christine.desmedt@bordet.be</email></address><xref ref-type="aff" rid="Aff10"/></contrib><contrib contrib-type="author"><name><surname>Gacquer</surname><given-names>David</given-names></name><address><email>dgacquer@ulb.ac.be</email></address><xref ref-type="aff" rid="Aff12"/></contrib><contrib contrib-type="author"><name><surname>Michiels</surname><given-names>Stefan</given-names></name><address><email>stefan.michiels@gustaveroussy.fr</email></address><xref ref-type="aff" rid="Aff13"/><xref ref-type="aff" rid="Aff14"/></contrib><contrib contrib-type="author"><name><surname>Roth&#x000e9;</surname><given-names>Fran&#x000e7;oise</given-names></name><address><email>francoise.rothe@bordet.be</email></address><xref ref-type="aff" rid="Aff10"/></contrib><contrib contrib-type="author"><name><surname>Majjaj</surname><given-names>Samira</given-names></name><address><email>samira.majjaj@bordet.be</email></address><xref ref-type="aff" rid="Aff10"/></contrib><contrib contrib-type="author"><name><surname>Salgado</surname><given-names>Roberto</given-names></name><address><email>roberto.salgado@telenet.be</email></address><xref ref-type="aff" rid="Aff15"/></contrib><contrib contrib-type="author"><name><surname>Larsimont</surname><given-names>Denis</given-names></name><address><email>denis.larsimont@bordet.be</email></address><xref ref-type="aff" rid="Aff16"/></contrib><contrib contrib-type="author"><name><surname>Ignatiadis</surname><given-names>Michail</given-names></name><address><email>michail.ignatiadis@bordet.be</email></address><xref ref-type="aff" rid="Aff10"/></contrib><contrib contrib-type="author"><name><surname>Maetens</surname><given-names>Marion</given-names></name><address><email>marion.maetens@bordet.be</email></address><xref ref-type="aff" rid="Aff10"/></contrib><contrib contrib-type="author"><name><surname>Piccart</surname><given-names>Martine</given-names></name><address><email>martine.piccart@bordet.be</email></address><xref ref-type="aff" rid="Aff15"/></contrib><contrib contrib-type="author"><name><surname>Detours</surname><given-names>Vincent</given-names></name><address><email>vdetours@ulb.ac.be</email></address><xref ref-type="aff" rid="Aff12"/></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name><surname>Sotiriou</surname><given-names>Christos</given-names></name><address><email>christos.sotiriou@bordet.be</email></address><xref ref-type="aff" rid="Aff10"/></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name><surname>Haibe-Kains</surname><given-names>Benjamin</given-names></name><address><email>bhaibeka@uhnresearch.ca</email></address><xref ref-type="aff" rid="Aff17"/><xref ref-type="aff" rid="Aff18"/></contrib><aff id="Aff10"><label/>Breast Cancer Translational Research Laboratory (BCTL), Institut Jules Bordet, Brussels, Belgium </aff><aff id="Aff11"><label/>Bioinformatics Core Facility, Institut de Recherches cliniques de Montr&#x000e9;al, Montreal, QC Canada </aff><aff id="Aff12"><label/>IRIBHM, Universit&#x000e9; Libre de Bruxelles, Campus Erasme, Brussels, Belgium </aff><aff id="Aff13"><label/>Department of Biostatistics and Epidemiology, Institut Gustave-Roussy, Villejuif, France </aff><aff id="Aff14"><label/>Paris-Sud University, Paris, France </aff><aff id="Aff15"><label/>Breast International Group, Brussels, Belgium </aff><aff id="Aff16"><label/>Department of Pathology, Institut Jules Bordet, Brussels, Belgium </aff><aff id="Aff17"><label/>Princess Margaret Cancer Centre, University Health Network, Toronto, ON Canada </aff><aff id="Aff18"><label/>Medical Biophysics Department, University of Toronto, Toronto, ON Canada </aff></contrib-group><pub-date pub-type="epub"><day>21</day><month>11</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>15</volume><issue>1</issue><elocation-id>1008</elocation-id><history><date date-type="received"><day>5</day><month>8</month><year>2014</year></date><date date-type="accepted"><day>10</day><month>11</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; Fumagalli et al.; licensee BioMed Central Ltd. 2014</copyright-statement><license license-type="open-access"><license-p>This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Microarrays have revolutionized breast cancer (BC) research by enabling studies of gene expression on a transcriptome-wide scale. Recently, RNA-Sequencing (RNA-Seq) has emerged as an alternative for precise readouts of the transcriptome. To date, no study has compared the ability of the two technologies to quantify clinically relevant individual genes and microarray-derived gene expression signatures (GES) in a set of BC samples encompassing the known molecular BC&#x02019;s subtypes. To accomplish this, the RNA from 57 BCs representing the four main molecular subtypes (triple negative, HER2 positive, luminal A, luminal B), was profiled with Affymetrix HG-U133 Plus 2.0 chips and sequenced using the Illumina HiSeq 2000 platform. The correlations of three clinically relevant BC genes, six molecular subtype classifiers, and a selection of 21 GES were evaluated.</p></sec><sec><title>Results</title><p>16,097 genes common to the two platforms were retained for downstream analysis. Gene-wise comparison of microarray and RNA-Seq data revealed that 52% had a Spearman&#x02019;s correlation coefficient greater than 0.7 with highly correlated genes displaying significantly higher expression levels. We found excellent correlation between microarray and RNA-Seq for the estrogen receptor (ER; r<sub>s</sub> = 0.973; 95% CI: 0.971-0.975), progesterone receptor (PgR; r<sub>s</sub> = 0.95; 0.947-0.954), and human epidermal growth factor receptor 2 (HER2; r<sub>s</sub> = 0.918; 0.912-0.923), while a few discordances between ER and PgR quantified by immunohistochemistry and RNA-Seq/microarray were observed. All the subtype classifiers evaluated agreed well (Cohen&#x02019;s kappa coefficients &#x0003e;0.8) and all the proliferation-based GES showed excellent Spearman correlations between microarray and RNA-Seq (all r<sub>s</sub> &#x0003e;0.965). Immune-, stroma- and pathway-based GES showed a lower correlation relative to prognostic signatures (all r<sub>s</sub> &#x0003e;0.6).</p></sec><sec><title>Conclusions</title><p>To our knowledge, this is the first study to report a systematic comparison of RNA-Seq to microarray for the evaluation of single genes and GES clinically relevant to BC. According to our results, the vast majority of single gene biomarkers and well-established GES can be reliably evaluated using the RNA-Seq technology.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/1471-2164-15-1008) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Breast cancer</kwd><kwd>Gene expression signatures</kwd><kwd>Affymetrix</kwd><kwd>Microarray</kwd><kwd>Illumina</kwd><kwd>RNA-Seq</kwd><kwd>Immunohistochemistry</kwd><kwd>Estrogen receptor</kwd><kwd>Progesterone receptor</kwd><kwd>HER2 receptor</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>For more than a decade, microarrays have represented the most comprehensive approach to measuring gene expression levels [<xref ref-type="bibr" rid="CR1">1</xref>]. Their ability to simultaneously assess thousands of transcripts, coupled with relatively low experimentation costs and the broad availability of analytical tools, have facilitated their wide use and led to fundamental advances in several research fields. In breast cancer, implementing gene expression microarrays has broadened our knowledge about the biology of the disease, which has, for many years, relied on immunohistochemistry (IHC) and clinical-pathologic parameters only. Several studies have shown that breast cancers can be classified into at least four &#x0201c;intrinsic&#x0201d; subtypes (basal-like, HER2 enriched, luminal A, and luminal B) which can only be partially recapitulated by IHC definitions of the three fundamental breast cancer biomarkers: estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2) [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>].</p><p>In current clinical practice, subtypes are defined mostly by using an IHC surrogate [<xref ref-type="bibr" rid="CR6">6</xref>]. Multiple expression-based classifiers have been developed, including two versions of the Subtype Classification Model (SCM) (SCMOD1 [<xref ref-type="bibr" rid="CR7">7</xref>] and SCMOD2 [<xref ref-type="bibr" rid="CR8">8</xref>]), and the simple three-gene model (SCMGENE [<xref ref-type="bibr" rid="CR9">9</xref>]) developed by Sotiriou and co-workers, as well as three variants of the Single Sample Predictor (SSP) (SSP2003 [<xref ref-type="bibr" rid="CR10">10</xref>], SSP2006 [<xref ref-type="bibr" rid="CR11">11</xref>] and PAM50 [<xref ref-type="bibr" rid="CR12">12</xref>]) developed by Perou and co-workers, the latter having been recently translated into a clinical assay (Prosigna<sup>&#x02122;</sup>[<xref ref-type="bibr" rid="CR13">13</xref>]). The computational implementation and comparison of these classifiers has been documented in [<xref ref-type="bibr" rid="CR9">9</xref>]. Microarrays have also been used to derive a series of gene expression signatures aimed at characterizing the biology of the disease and at helping clinicians predict relapse and response to treatment more accurately than tools using traditional clinico-pathological parameters [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>]. Some of these signatures have been endorsed by international breast cancer guidelines, and they are being increasingly implemented in standard practice [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p>In parallel, RNA sequencing (RNA-Seq) is emerging as the technology of reference for thorough characterization of the human transcriptome and as a superior alternative to microarrays to define gene expression levels [<xref ref-type="bibr" rid="CR28">28</xref>&#x02013;<xref ref-type="bibr" rid="CR31">31</xref>]. RNA-Seq is overcoming some of the drawbacks of microarrays [<xref ref-type="bibr" rid="CR28">28</xref>&#x02013;<xref ref-type="bibr" rid="CR32">32</xref>]. For instance, the dependence of microarrays on hybridization of transcripts to pre-determined probes restricts analysis to genes for which genomic sequence information is available first-hand and to sequences that are distant enough so that probes do not cross-hybridize. Moreover, high levels of background noise arising from non-specific hybridization and probe saturation affect the quantification of transcripts expressed at low and high levels, respectively, limiting the dynamic range of the technology. Although the RNA-Seq technology efficiently address these issues, the current lack of standards for analyzing these new data, coupled with the relatively high cost of the RNA-Seq experiments, could deter investigators from implementing the technology in their activity.</p><p>Several studies have been carried out to compare the performance of RNA-Seq and microarrays, including exon arrays, in defining levels of gene expression [<xref ref-type="bibr" rid="CR33">33</xref>&#x02013;<xref ref-type="bibr" rid="CR42">42</xref>]. The vast majority of them have focused on establishing the reliability of RNA-Seq in differential gene expression (DGE) analyses between two or more samples and/or conditions of interest. Despite the fact that they have generally reported good correlation between the two technologies, most of these studies have relied on relatively few samples or exclusively on non-human samples. Moreover, they have never attempted to assess the performance of RNA-Seq in defining clinically relevant biomarkers developed using microarrays. Given the promise of microarray-based gene signatures [<xref ref-type="bibr" rid="CR43">43</xref>] and the significant advantages of the new RNA-Seq technology in providing more accurate and reliable gene expression measurements, there is a dire need to investigate the transition of breast cancer gene signatures from microarray to RNA-Seq.</p><p>The main aim of the current study is to compare the agreement between two of the most widely used microarray and RNA-Seq platforms, Affymetrix and Illumina HiSeq respectively, in estimating (1) the expression of single genes which are clinically relevant to breast cancer and (2) breast cancer subtype classifiers and gene expression signatures that have been developed over the years with microarrays. The comparison uses a dataset obtained from well characterized breast cancer patients representing the four main breast cancer subtypes: triple negative, HER2 positive, luminal A, and luminal B.</p></sec><sec id="Sec2" sec-type="methods"><title>Methods</title><sec id="Sec3"><title>Sample selection and characterization</title><p>Fresh-frozen tumor material was obtained from 57 breast cancer patients who were treated at Institut Jules Bordet (Brussels, Belgium) between 2007 and 2011 and whose samples were stored at the institute&#x02019;s biorepository. The samples represented the four main known breast cancer subtypes (by IHC) and their tumor cell content evaluated on a hematoxylin-eosin (H&#x00026;E) slide by a board-certified breast cancer pathologist was greater than or equal to 30%. Of the 57 patients, 17 had triple negative breast cancer (TN: ER, PgR, and HER2 negative), 14 HER2 positive (any ER and PgR, HER2 positive), 16 luminal A (ER, HER2 negative, histological grade 1), and 10 luminal B (ER, HER2 negative, histological grade 3). The use of the tumor material is consistent with the informed consent signed by the patients and was granted approval by Institut Jules Bordet&#x02019;s ethics committee (approval number: CE1967), and is in accordance with the applicable laws and regulations in Belgium.</p></sec><sec id="Sec4"><title>RNA extraction</title><p>RNA was extracted using TRIzol&#x000ae; (Life Technologies, Carlsbad, California) following the manufacturer&#x02019;s instructions. Concentration was measured using the NanoDrop 1000 (Thermo Scientific, Waltham, Massachusetts), and integrity (RIN: RNA Integrity Number) was assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, California). All the samples yielded enough material for downstream experiments, and had a RIN equal to or greater than 6.5. RNA obtained from the same extraction procedure was profiled on microarrays and sequenced on the Illumina HiSeq 2000.</p></sec><sec id="Sec5"><title>Microarray experiments</title><p>100&#x000a0;ng of total RNA was profiled at the Institut Jules Bordet using the Affymetrix&#x000ae; HG-U133 Plus 2.0 Arrays (Affymetrix, Santa Clara, California), following the manufacturer&#x02019;s instructions. Briefly, the RNA was first reverse-transcribed into double-stranded cDNA. This cDNA was transcribed in vitro. After purification of the aRNA, 12.5&#x000a0;&#x003bc;g were fragmented and labeled prior to hybridization to the chips. Quality control (QC) for each chip was performed following the recommendations posted on [<xref ref-type="bibr" rid="CR44">44</xref>]. Following QC, the probe level intensities were background adjusted and quantile normalized using the Frozen Robust Multiarray Analysis (fRMA) method [<xref ref-type="bibr" rid="CR45">45</xref>] as implemented in the R/Bioconductor package fmra [<xref ref-type="bibr" rid="CR46">46</xref>]. Probeset level annotations were obtained from R/Bioconductor package jetset [<xref ref-type="bibr" rid="CR47">47</xref>] and complemented with BioMart [<xref ref-type="bibr" rid="CR48">48</xref>]; when multiple probesets mapped to the same Entrez Gene ID, the probeset with the highest jetset score was selected. The raw Affymetrix CEL files are available from the NCBI&#x02019;s Gene Expression Omnibus under accession number GSE43358.</p><p>The data can be accessed through this link: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=trmzbecoaqyugtc&#x00026;acc=GSE43358">http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=trmzbecoaqyugtc&#x00026;acc=GSE43358</ext-link>.</p></sec><sec id="Sec6"><title>RNA-Seq sample preparation and sequencing</title><p>Transcriptome sequencing was performed at DNAVision (Gosselies, Belgium). Transcriptome libraries were constructed using the Illumina &#x000ae; TruSeq&#x02122; RNA Sample Preparation Kit for paired-end reads sequencing on the HiSeq 2000 (Illumina, San Diego, California) following the manufacturer&#x02019;s instructions. Briefly, starting from 1&#x000a0;&#x003bc;g of total RNA, the poly-A containing mRNA molecules were purified using poly-T oligo-attached magnetic beads. Following purification, the mRNA was fragmented into small pieces using divalent cations under elevated temperature. The cleaved RNA fragments were copied into first strand cDNA using reverse transcriptase and random primers. This was followed by second strand cDNA synthesis using DNA Polymerase I and RNase H and purification using the AMPure XP beads (Agencourt BioSciences Corporation, Beverly, Massachusetts). The cDNA fragments were end repaired with the addition of a single &#x02018;A&#x02019; base and the ligation of adapters. The products were purified using the AMPure XP beads and enriched with PCR (15&#x000a0;cycles) to create the final cDNA library followed by purification using the AMPure XP beads. Library quality control and quantification were performed using the Agilent Bioanalyser 2100 and qRT-PCR. The libraries were then pooled (4 libraries/pool). Clusters were generated in a cBot Cluster Generation System using the Paired-End Cluster Generation Kit v2-HS and sequenced on the Illumina&#x000ae; HiSeq 2000 platform with a 2x50 base-pairs paired-end mode. Base calls were made using the Illumina CASAVA 1.5 pipeline. Sequence data has been deposited at the European Genome-phenome Archive (EGA), which is hosted by the EBI and the CRG [<xref ref-type="bibr" rid="CR49">49</xref>], under study&#x02019;s accession number EGAS00001000495 and dataset&#x02019;s accession number EGAD00001000626.</p></sec><sec id="Sec7"><title>Assessment of RNA-Seq data quality</title><p>The following statistics were computed to verify the quality of the RNA-Seq data (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1). The total number of paired reads, the average Phred quality scores, and the average GC content were calculated on the quality trimmed FASTQ files with FastQC [<xref ref-type="bibr" rid="CR50">50</xref>]. The percentage of &#x0201c;proper pairs&#x0201d;, defined as mapped paired reads with an insert size ranging from 60 to 160&#x000a0;bp, was calculated with BamTools [<xref ref-type="bibr" rid="CR51">51</xref>]. The percentage of aligned duplicate read pairs was calculated with Picard tools MarkDuplicates [<xref ref-type="bibr" rid="CR52">52</xref>].</p></sec><sec id="Sec8"><title>RNA-Seq analysis</title><p>After trimming the poor quality bases, the reads were mapped to the human reference genome hg19 with TopHat2 (version 2.0.0) [<xref ref-type="bibr" rid="CR53">53</xref>], and gene expression was quantified with Cufflinks (version 2.0.0) [<xref ref-type="bibr" rid="CR53">53</xref>]. The annotation file (GTF file) used for both alignment and gene quantification was downloaded from Ensembl (on 26 July, 2012). To match the log scale of gene expression measurements from the microarray data, the FPKM (Fragments Per Kilobase of transcript per Million mapped reads) values computed by Cufflinks were log-transformed using the following formula:<disp-formula id="Equa"><graphic xlink:href="12864_2014_6829_Equa_HTML.gif" position="anchor"/></disp-formula></p><p>where X represents the FPKM value computed by Cufflinks, and X&#x02019; is the log-transformed expression value.</p></sec><sec id="Sec9"><title>Gene expression signatures</title><p>Our study focused on the following gene expression signatures: (1) six prognostic signatures (GENE70 [<xref ref-type="bibr" rid="CR14">14</xref>], GENE21 [<xref ref-type="bibr" rid="CR15">15</xref>], Genomic Grade Index (GGI [<xref ref-type="bibr" rid="CR16">16</xref>]), Risk of Relapse-Score (ROR-S [<xref ref-type="bibr" rid="CR12">12</xref>]), ENDOPREDICT [<xref ref-type="bibr" rid="CR17">17</xref>], and CIN70 [<xref ref-type="bibr" rid="CR18">18</xref>]); (2) two immune signatures (STAT1MODULE [<xref ref-type="bibr" rid="CR7">7</xref>] and IRMODULE [<xref ref-type="bibr" rid="CR19">19</xref>]); (3) three stroma-related signatures (PLAUMODULE [<xref ref-type="bibr" rid="CR7">7</xref>], DCN [<xref ref-type="bibr" rid="CR20">20</xref>], and STROMACD10 [<xref ref-type="bibr" rid="CR21">21</xref>]); and (4) ten pathway related signatures (PIK3CA-GS [<xref ref-type="bibr" rid="CR22">22</xref>], PTEN loss [<xref ref-type="bibr" rid="CR23">23</xref>], IGF1 [<xref ref-type="bibr" rid="CR24">24</xref>], AKT/mTOR [<xref ref-type="bibr" rid="CR25">25</xref>], MAPK [<xref ref-type="bibr" rid="CR26">26</xref>], SRC, RAS, MYC, E2F3, and beta-catenin [<xref ref-type="bibr" rid="CR27">27</xref>]). We also evaluated six subtype classifiers: SCMOD1 [<xref ref-type="bibr" rid="CR7">7</xref>], SCMOD2 [<xref ref-type="bibr" rid="CR8">8</xref>], SCMGENE [<xref ref-type="bibr" rid="CR9">9</xref>], SSP2003 [<xref ref-type="bibr" rid="CR10">10</xref>], SSP2006 [<xref ref-type="bibr" rid="CR11">11</xref>], and PAM50 [<xref ref-type="bibr" rid="CR12">12</xref>]. In addition to these multivariate subtyping models, we evaluated the three individual breast cancer clinically relevant genes: ER, PgR, and HER2.</p><p>We used the original signature algorithms for GENE70, GENE21, GGI, ROR-S, ENDOPREDICT, CIN70, STAT1MODULE, PLAUMODULE, DCN and STROMACD10 as implemented in the Bioconductor package <italic>genefu</italic>[<xref ref-type="bibr" rid="CR54">54</xref>]. For the remaining gene expression signatures, we computed the signature scores following the approach used in Ignatiadis et al. [<xref ref-type="bibr" rid="CR55">55</xref>]. The scores were computed from the list of genes in their respective signatures (as listed in GeneSigDB [<xref ref-type="bibr" rid="CR56">56</xref>]) as the weighted average using the following formula:
<disp-formula id="Equb"><graphic xlink:href="12864_2014_6829_Equb_HTML.gif" position="anchor"/></disp-formula></p><p>where <italic>s</italic> is the signature score, <italic>n</italic> is the number of genes in the signature of interest, <italic>x</italic><sub><italic>i</italic></sub> is the expression of the gene, and the gene-specific weight <italic>w</italic><sub><italic>i</italic></sub> &#x02208; {&#x02212;1,1} is the sign of the coefficient defined in the original publication. Only genes that could be mapped to EntrezGene IDs were used. Finally, each signature score was rescaled so that the 2.5% and 97.5% quantiles were equal to +1 and &#x02212;1 respectively.</p></sec><sec id="Sec10"><title>Data analysis</title><p>The pair-wise correlation between Affymetrix microarrays and Illumina RNA-Seq gene expression data and gene expression signatures scores was assessed using Spearman&#x02019;s rank-based correlation. For the three single gene biomarkers (ER, PgR and HER2), the correlation between microarray or RNA-Seq with IHC was estimated to identify which technology provided better concordance with IHC. Cohen&#x02019;s kappa coefficient was used to compare the subtype classifications from microarray or RNA-Seq data. To statistically compare the Spearman correlation and Cohen&#x02019;s kappa coefficients of different gene signatures, we used a two-sided Wilcoxon rank sum test with 100 bootstrap replicates of the 57 patients to determine the p-value. The resulting p-values, reporting the significance of the correlation difference between each pair of gene expression signatures, were corrected for multiple testing using Bonferroni&#x02019;s method.</p><p>To compare the correlation of gene expression over the whole transcriptome between each pair of data type from a given sample, we used Spearman&#x02019;s rank-based correlation, the null distribution of which was established as the range of coefficients observed from all possible combinations of the 57 pairs excluding self-self pairs. This is efficiently computed from the cross correlation matrix minus the diagonal elements. The analyses performed in this study are fully reproducible and comply with proposed guidelines in terms of availability of the code and data [<xref ref-type="bibr" rid="CR57">57</xref>]. The R scripts developed for the analysis are available upon request.</p></sec><sec id="Sec11"><title>Data availability</title><p>The raw Affymetrix CEL files are available from the NCBI&#x02019;s Gene Expression Omnibus under accession number GSE43358. The data can be accessed through this link: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=trmzbecoaqyugtc&#x00026;acc=GSE43358">http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=trmzbecoaqyugtc&#x00026;acc=GSE43358</ext-link>.</p><p>Sequence data has been deposited at the European Genome-phenome Archive (EGA), which is hosted by the EBI and the CRG [<xref ref-type="bibr" rid="CR49">49</xref>], under study&#x02019;s accession number EGAS00001000495 and dataset&#x02019;s accession number EGAD00001000626.</p></sec></sec><sec id="Sec12" sec-type="results"><title>Results</title><sec id="Sec13"><title>Gene-wise comparison of expression levels using Affymetrix microarray and Illumina RNA-Seq platforms</title><p>A subset of 16,097 genes were defined as common to the two platforms and retained for downstream analysis. Gene identifiers did not perfectly overlap due to differences in the annotation systems: jetset matched the Affymetrix probesets to the NCBI RefSeq human cDNA database, while the RNA-Seq analysis pipeline used Ensembl gene annotations (see Methods for more detail). When comparing the expression levels of the genes retained after selection of the best Affymetrix probeset, we found that although the scale of expression values differs due to different technology and normalization procedures, their rank is well conserved with 52%, 34%, and 11% of these genes having Spearman&#x02019;s rank-based correlation greater than 0.7, 0.8, and 0.9, respectively (Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>A). The Spearman correlation coefficient for each evaluated gene is reported in Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2.<fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>Gene expression correlation between Affymetrix microarray and Illumina RNA-Seq platforms. A:</bold> Expression correlation of the 16,097 genes measured both on Affymetrix microarray and Illumina RNA-Seq platforms after selecting the best Affymetrix probeset using jetset. <bold>B:</bold> and <bold>C:</bold> Box plots showing median level of gene expression for both Affymetrix and RNA-Seq for the genes with low (&#x0003c;0.7) and high (&#x02265;0.7) correlation. Genes highly correlated between the two platforms showed higher levels of expression than those with low correlation.</p></caption><graphic xlink:href="12864_2014_6829_Fig1_HTML" id="d30e846"/></fig></p><p>We observed that genes with the highest correlation coefficients for the comparison of microarray and RNA-Seq were significantly more expressed. Similarly, the genes that were positively correlated were significantly more expressed than genes that were negatively correlated (two-sided Wilcoxon rank sum test p-value &#x0003c;1x10<sup>&#x02212;16</sup>; Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Figure S1). This result holds true when considering a high cutoff of correlation r<sub>s</sub> &#x02265;0.7 (two-sided Wilcoxon rank sum test p-value &#x0003c;1x10<sup>&#x02212;16</sup>; Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>B and <xref rid="Fig1" ref-type="fig">1</xref>C). This phenomenon could be explained by the potentially higher variance of genes expressed at low levels [<xref ref-type="bibr" rid="CR58">58</xref>] or by the fact that microarrays have a limited dynamic range compared to RNA-Seq [<xref ref-type="bibr" rid="CR28">28</xref>&#x02013;<xref ref-type="bibr" rid="CR32">32</xref>].</p><p>In order to investigate this phenomenon more deeply, we computed the correlation for genes with cumulative increasing expression (Additional file <xref rid="MOESM3" ref-type="media">3</xref>: Figure S2). By starting with genes expressed at low levels and increasing gene expression levels by increments of 1%, we observed a steep rise in the median correlation coefficient; in contrast, the magnitude of the decrease moving away from genes expressed at high levels was much lower. These results suggest that, despite the potential saturation of microarrays for highly expressed genes, the correlation between the two technologies remains high; however, we observed a high-level of inconsistency for genes expressed at low levels, either originating from microarray or RNA-seq technology, or both.</p><p>We acknowledge from past experience with gene expression microarrays that, when comparing the whole transcriptome, two unrelated samples may have a correlation coefficient that is as high as two arrays performed on the same sample, raising questions about the significance of an asymptotic p-value in that particular setting. In our dataset, the correlation of gene expression profiles for the whole transcriptome measured by microarray and RNA-Seq was statistically significant for all except three patients (Additional file <xref rid="MOESM4" ref-type="media">4</xref>: Figure S3).</p></sec><sec id="Sec14"><title>Definition of ER, PgR, and HER2 status according to IHC, microarray, and RNA-Seq</title><p>Among the genes retained for analysis, we focused our attention on three that are clinically relevant for breast cancer: ER, PgR, and HER2. Measuring them precisely is of utmost importance to clinical practice as these are presently the only validated breast cancer predictive biomarkers available, and they are routinely used to make decisions about patient treatment [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR59">59</xref>].When comparing the expression levels of these three genes as defined by microarray and RNA-Seq, we found excellent Spearman correlation coefficients: 0.973 for ER [95% CI: 0.971-0.975]; 0.95 for PgR [95% CI: 0.947-0.954]; and 0.918 for HER2 [95% CI: 0.912-0.923] (Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Figure 2</label><caption><p>
<bold>Expression correlation for ER, PgR, and HER2 genes.</bold> Scatterplots reporting the expression correlation of ER, PgR, and HER2 defined by Affymetrix microarray or Illumina RNA-Seq. Each dot is colored according to the corresponding status determined by IHC: green for positive, blue for negative, red for borderline. Spearman correlation coefficient and p-value are provided below the plots.</p></caption><graphic xlink:href="12864_2014_6829_Fig2_HTML" id="d30e912"/></fig></p><p>We then went a step further and compared the gene expression levels defined by either RNA-Seq or Affymetrix with IHC, which is currently considered to be the methodology of reference for the definition of these markers, together with FISH for HER2 [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR61">61</xref>]. Overall, a good correlation was found between the technologies (r<sub>s</sub> &#x0003e;0.69), and only a few discordances were observed (Additional file <xref rid="MOESM5" ref-type="media">5</xref>: Figure S4).</p></sec><sec id="Sec15"><title>Correlation between technologies for the definition of breast cancer subtype classifiers</title><p>Two different gene expression approaches have been developed to prospectively classify breast cancers into molecular subtypes: Subtype Classification Models (SCMs) [<xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>] and Single Sample Predictors (SSPs) [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>], which include PAM50. In the current dataset, our subtype classifier SCMOD2 [<xref ref-type="bibr" rid="CR8">8</xref>] showed the highest correlation between microarray and RNA-Seq technologies (&#x003ba; = 0.975; Figure&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>A, Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S3), which was significantly higher than the other classifiers (100 bootstrap replicates, corrected p-value &#x0003c;0.001; Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S4). Of note, although the kappa coefficients for SCMGENE [<xref ref-type="bibr" rid="CR9">9</xref>] and PAM50 [<xref ref-type="bibr" rid="CR12">12</xref>] were very similar (&#x003ba; = 0.903 vs. 0.902 for SCMGENE and PAM50, respectively), SCMGENE was more concordant than PAM50 in our study (corrected p-value = 0.001, Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S4).<fig id="Fig3"><label>Figure 3</label><caption><p>
<bold>Correlation values for the evaluated subtype classifiers and gene expression signatures. A:</bold> Cohen&#x02019;s Kappa coefficients for subtype classifiers (orange: SCMs; purple: SSPs). <bold>B:</bold> Spearman correlation values for prognostic (orange), immune (green), stroma (blue) and pathway (purple) signature scores as computed using Affymetrix microarray and Illumina RNA-Seq platforms.</p></caption><graphic xlink:href="12864_2014_6829_Fig3_HTML" id="d30e981"/></fig></p></sec><sec id="Sec16"><title>Correlation between technologies: gene prognostic signatures</title><p>Using microarray technology, several prognostic gene expression signatures have been developed in the attempt to help clinicians to identify which breast cancers are at high or low risk of recurrence [<xref ref-type="bibr" rid="CR43">43</xref>]. Among these, MammaPrint&#x000ae; (here referred to as GENE70) [<xref ref-type="bibr" rid="CR14">14</xref>], OncotypeDx&#x000ae; (here referred to as GENE21) [<xref ref-type="bibr" rid="CR15">15</xref>], GGI [<xref ref-type="bibr" rid="CR16">16</xref>], ENDOPREDICT [<xref ref-type="bibr" rid="CR17">17</xref>] and ROR-S [<xref ref-type="bibr" rid="CR12">12</xref>] have been widely investigated and applied in the clinical setting. When comparing the values of these signatures on a continuum as defined by either microarray or RNA-Seq, an excellent Spearman correlation was found: 0.97 [95% CI 0.968-0.972] for GENE70; 0.965 [95% CI 0.962-0.967] for GENE21; 0.985 [95% CI 0.984-0.986] for GGI; 0.979 [95%CI 0.977,0.981] for ENDOPREDICT; and 0.965 (95% CI 0.962,0.967) for ROR-S (Figure&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>).<fig id="Fig4"><label>Figure 4</label><caption><p>
<bold>Risk prediction scores of the commercially available prognostic signatures.</bold> Scatterplots reporting the continuous risk prediction scores of the commercially available prognostic signatures. Each dot is colored according to the corresponding risk classification: blue for concordant low-risk, orange for concordant intermediate risk, green for concordant high-risk and red for discordance. The cutoff used to discretize the continuous risk predictions into risk classifications are represented in dashed red lines. Spearman correlation coefficient and p-value are provided below the plots.</p></caption><graphic xlink:href="12864_2014_6829_Fig4_HTML" id="d30e1020"/></fig></p></sec><sec id="Sec17"><title>Correlation between technologies: immune, stroma and pathway related gene expression signatures</title><p>After a first wave of prognostic signatures, which essentially captured tumor proliferation signals, a new generation of &#x0201c;biological&#x0201d; signatures were developed that focused on determining the prognostic and/or predictive role of host-tumor immune interplay, tumor microenvironment and pathway activation signaling. We evaluated the correlation between microarray and RNA-Seq platforms in measuring the following: 1) two immune signatures (STAT1MODULE [<xref ref-type="bibr" rid="CR7">7</xref>], IRMODULE [<xref ref-type="bibr" rid="CR19">19</xref>]); 2) three stroma signatures (PLAUMODULE [<xref ref-type="bibr" rid="CR7">7</xref>], DCN [<xref ref-type="bibr" rid="CR20">20</xref>], STROMACD10 [<xref ref-type="bibr" rid="CR21">21</xref>]); and 3) ten pathway signatures (PIK3CA-GS [<xref ref-type="bibr" rid="CR22">22</xref>], PTEN loss [<xref ref-type="bibr" rid="CR23">23</xref>], IGF1 [<xref ref-type="bibr" rid="CR24">24</xref>], AKT/mTOR [<xref ref-type="bibr" rid="CR25">25</xref>], MAPK [<xref ref-type="bibr" rid="CR26">26</xref>], SRC, RAS, MYC, E2F3, beta-catenin [<xref ref-type="bibr" rid="CR27">27</xref>]).As shown in Figure&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>B, the Spearman correlation coefficients were better overall for the prognostic signatures than the biological ones (corrected p-value &#x0003c;0.001). This was particularly the case for the pathway signatures.</p></sec><sec id="Sec18"><title>Signature enrichment in highly expressed genes and correlation between technologies</title><p>Since higher correlation coefficients were found for genes expressed at higher levels, we investigated whether enrichment in genes with higher expression in the above subtype classifiers and gene expression signatures could have affected their correlation when defined with the two technologies. We found that 81% (22/27) and 74% (20/27) of the signatures were significantly enriched with highly expressed genes for Affymetrix microarray and Illumina RNA-seq platforms, respectively (p-value &#x0003c;0.05; Additional file <xref rid="MOESM6" ref-type="media">6</xref>: Figure S5 and Additional file <xref rid="MOESM7" ref-type="media">7</xref>: Figure S6). However such enrichment did not imply significantly higher correlation between the two platforms, suggesting that the proportion of highly expressed genes is not solely responsible for the highest correlations observed in our study.</p></sec></sec><sec id="Sec19" sec-type="discussion"><title>Discussion</title><p>The use of molecular tools in clinical practice is on the rise. In breast cancer, international guidelines endorse the implementation of microarray-derived gene signatures to support clinicians in the treatment decision-making process [<xref ref-type="bibr" rid="CR6">6</xref>]. In addition, the upcoming results of two genome-forward clinical trials, namely the MINDACT and the TailorX trials [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>], involving thousands of patients, will provide the highest level of evidence to date about whether basing clinical decisions on microarray-derived prognostic gene signatures influences the outcome of breast cancer patients. The parallel rise of RNA-Seq as an accurate and reliable alternative to microarrays for transcriptome characterization and gene expression quantification is puzzling for investigators, who must decide which technology best fulfills their clinical needs. Hence, it is imperative to determine the reliability of transitioning from microarray to sequencing platforms in the clinical setting. To our knowledge, our is the first report investigating the correlation between the expression level of single clinically relevant genes and gene expression signatures obtained with the most commonly used microarray and RNA-Seq platforms, Affymetrix and Illumina respectively, in a selected dataset of breast cancer patients.</p><p>When focusing on the genes in common between the two platforms, our analysis showed that the expression of more than half of them had a Spearman correlation of 0.7. This was the case simply by selecting the most specific Affymetrix probeset and correlating it to gene log2 transformed FPKM obtained at sequencing, without any further computation. In studies exploring the correlation of the two technologies in defining genes differentially expressed among samples and/or conditions, the correlation values of fold change ratios were reported to range from 0.55 to 0.85 [<xref ref-type="bibr" rid="CR33">33</xref>&#x02013;<xref ref-type="bibr" rid="CR42">42</xref>]. Of note, these values are similar to or higher than the correlation observed across different microarray platforms [<xref ref-type="bibr" rid="CR64">64</xref>]. In these same studies, RNA-Seq seemed to be more reliable than microarray in identifying differential gene expression: in several reports, a large proportion of genes identified as differentially expressed by RNA-Seq but not by microarray were in fact confirmed by qPCR [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR65">65</xref>]. RNA-Seq also seems more suitable than microarrays to quantify absolute gene expression levels when compared with mass spectrometry measurements [<xref ref-type="bibr" rid="CR35">35</xref>].</p><p>As reported by other investigators [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR65">65</xref>], we found that the correlation of genes was higher when their expression levels were higher. The reliance of microarrays on the presence of primers and probes limits their ability to measure extreme gene expressions; according to our data, the limitation seems to be more relevant in the low expression range. On the contrary, the nature of sequencing technologies allows the unbiased investigation of gene expression when enough depth is assured.</p><p>In our study, RNA-Seq showed high correlation with microarrays when measuring clinically relevant genes in breast cancer (i.e., ER, PgR, and HER2). Nevertheless, despite an overall good correlation, both technologies showed a few discordances when compared to IHC. Similar results have already been reported when comparing microarray with IHC [<xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR67">67</xref>]. These discordances might be partly attributed to the fact that IHC measures the expression of ER, PgR, and HER2 at the protein level, while both Affymetrix and RNA-Seq measure the expression levels of the corresponding mRNAs. Although mRNA and protein expression levels are not fully independent, one cannot exclude that post-transcriptional regulation might affect their correlation. Another factor that could account for these discordances is tumor heterogeneity. The expression levels of the three markers can in fact vary across different areas of the tumor. While the RNA profiled on microarray and sequenced on the Illumina platform was obtained from the same tumor area, the slides used for IHC staining were cut from a distinct area of the tumor lesion. The best way to capture the activity level of these receptors and their downstream pathways remains largely unclear. It is possible that the determination of ER, PgR, and HER2 status at the mRNA level could provide clinicians with a more reproducible, quantitative, and informative assessment of these markers [<xref ref-type="bibr" rid="CR68">68</xref>, <xref ref-type="bibr" rid="CR69">69</xref>]. For the time being, however, not enough evidence is available to recommend mRNA-based measurements for clinical practice.</p><p>Because of the clinical relevance of breast cancer subtypes, much attention has been paid to the performance of microarray-derived subtype classifiers. Some concerns have been raised about their reliability though. It has been shown that although every SSP can consistently identify molecular subtypes with different levels of survival, they do not reliably assign the same patients to the same molecular subtype [<xref ref-type="bibr" rid="CR70">70</xref>]. Variation in gene expression data and classification algorithms could influence how samples are classified into each subtype. In our study, the best correlation between microarray and RNA-Seq was obtained for SCMOD2 [<xref ref-type="bibr" rid="CR8">8</xref>], one of the subtype classifiers developed by our group. Similar correlation coefficients were obtained for PAM50 [<xref ref-type="bibr" rid="CR12">12</xref>] and SCMGENE [<xref ref-type="bibr" rid="CR9">9</xref>], with the latter showing slightly higher concordance. This result suggests the higher robustness of SCMGENE to small perturbations, which concurs with our recent robustness study [<xref ref-type="bibr" rid="CR9">9</xref>]. However, it is unlikely that Prosigna<sup>&#x02122;</sup>, the recent clinical assay implementing PAM50 using the NanoString&#x000ae; platform, would suffer the same limitation since its analytical validity has been thoroughly assessed [<xref ref-type="bibr" rid="CR13">13</xref>].</p><p>Given the increasing implementation of microarray-derived gene signatures in clinical practice, it is vital to determine if RNA-Seq could reliably be used to define them. When considering 21 of the most relevant signatures developed in recent years [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>], we found that the correlation values for microarray and RNA-Seq for signature determination ranged from moderate to very strong. Correlation values were higher for prognostic signatures than biological signatures, independently from their enrichment in highly expressed genes. This suggests that proliferation, which drives prognostic signatures, is more robust and reproducible than signals coming from other biological processes and that complex signatures developed on microarrays might be less stable.</p></sec><sec id="Sec20" sec-type="conclusions"><title>Conclusions</title><p>In our study, we have demonstrated that RNA-Seq can reliably be used to evaluate both the expression of clinically relevant single genes and well established gene expression signatures originally defined with microarray technology. Considering the advantages that RNA-Seq offers over microarray, such as its ability to explore larger sets of genes, it is envisaged that its application to wider datasets could even provide information relevant for de-novo classification of breast cancer or for the development of new prognostic and predictive signatures. With the cost of RNA-Seq experiments decreasing continuously and with well-established analytical tools increasingly available [<xref ref-type="bibr" rid="CR71">71</xref>&#x02013;<xref ref-type="bibr" rid="CR75">75</xref>], RNA-Seq is becoming an accessible tool that is superseding microarray in the research setting. We foresee that, with the aid of initiatives such as the SEquencing Quality Control (SEQC) consortium (the third phase of the FDA-led MAQC project) [<xref ref-type="bibr" rid="CR76">76</xref>] and studies such as ours confirming its reliability, RNA-Seq will eventually also supersede microarrays in the clinical setting.</p></sec><sec sec-type="supplementary-material"><title>Electronic supplementary material</title><sec id="Sec21"><supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12864_2014_6829_MOESM1_ESM.xls"><caption><p>Additional file 1: <bold>Table S1.</bold> Read statistics. &#x0201c;Proper pairs&#x0201d; are defined as reads where both pairs map to the reference genome with an inner distance between 60 and 160 bases. <bold>Table S2.</bold> Spearman correlation coefficients for each gene considered for comparison between Affymetrix microarray and Illumina RNA-Seq platforms. <bold>Table S3.</bold> Contingency table for breast cancer subtype classifiers (SCMs and SSPs) using Affymetrix microarray (AFFY) and Illumina RNA-Seq (RNASEQ) platforms. <bold>Table S4.</bold> Bootstrap analysis to assess the significance of the differences observed for Cohen&#x02019;s Kappa coefficients for subtype classifiers using Affymetrix microarray and Illumina RNA-Seq platforms. (XLS 6 MB)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="12864_2014_6829_MOESM2_ESM.pdf"><caption><p>Additional file 2: Figure S1: A and B: Box plots showing median level of expression on both Affymetrix microarray and Illumina RNA-Seq platforms for negatively and positively correlated genes. (PDF 9 KB)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="12864_2014_6829_MOESM3_ESM.pdf"><caption><p>Additional file 3: Figure S2: Correlation of gene expression levels between Affymetrix microarray and Illumina RNA-Seq platforms with respect to increasing quantiles of gene expression. (PDF 30 KB)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="12864_2014_6829_MOESM4_ESM.pdf"><caption><p>Additional file 4: Figure S3: Scatterplots reporting the point-to-point comparison of gene expression profiles measured by Affymetrix microarray and Illumina RNA-Seq platforms for each individual patient considered in the current study. Spearman correlation coefficient and p-value are provided below the plots. The solid line represents a linear regression of microarray values on the RNA-seq data while the dotted line has the equation y&#x02009;=&#x02009;x. (PDF 757 KB)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM5"><media xlink:href="12864_2014_6829_MOESM5_ESM.pdf"><caption><p>Additional file 5: Figure S4: Spearman correlation for the quantification of three clinically relevant genes (ER, PgR, and HER2) as defined by IHC vs Affymetrix microarray and Illumina RNA-Seq, respectively. (PDF 37 KB)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM6"><media xlink:href="12864_2014_6829_MOESM6_ESM.pdf"><caption><p>Additional file 6: Figure S5: Bar plots representing the proportion of genes present in all signatures combined (3,663 unique genes in 27 signatures) with respect to their quantiles of expression for Affymetrix microarray (blue) and Illumina RNA-seq (red) platforms. The p-value reports the significance of the enrichment of signature genes with increasing quantiles of expression (Spearman&#x02019;s rank-based correlation). (PDF 9 KB)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM7"><media xlink:href="12864_2014_6829_MOESM7_ESM.pdf"><caption><p>Additional file 7: Figure S6: Bar plots representing, for each signature (27), the proportion of genes present in all signatures combined with respect to their quantiles of expression for Affymetrix microarray (blue) and Illumina RNA-seq (red) platforms. The p-value reports the significance of the enrichment of signature genes with increasing quantiles of expression (Spearman&#x02019;s rank-based correlation). Note that the SCMGENE and IRMODULE signatures contains few genes (3 and 6 genes, respectively) while the median signature size is 95 genes; for these small signatures, the p-value is expected to be large due to reduce sample size for the correlation analysis. (PDF 36 KB)</p></caption></media></supplementary-material></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-list><def-item><term>RNA-Seq</term><def><p>RNA sequencing</p></def></def-item><def-item><term>BC</term><def><p>Breast cancer</p></def></def-item><def-item><term>GES</term><def><p>Gene expression signatures</p></def></def-item><def-item><term>fRMA</term><def><p>Frozen robust multiarray analysis</p></def></def-item><def-item><term>ER</term><def><p>Estrogen receptor</p></def></def-item><def-item><term>PgR</term><def><p>Progesterone receptor</p></def></def-item><def-item><term>HER2</term><def><p>Human epidermal growth factor receptor 2</p></def></def-item><def-item><term>IHC</term><def><p>Immunohistochemistry</p></def></def-item><def-item><term>FPKM</term><def><p>Fragments per kilobase per million mapped reads.</p></def></def-item></def-list></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>SC is inventor of the Genomic Grade Index (GGI); SC and DC are inventors of the immune signature; SC and HKB are inventors of the PIK3CA gene signature.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>Conceived and designed the study: FD, DC, MS, GD, IM, PM, DV, SC, HKB. Performed the experiments: FD, MS, MM, RF. Provided pathology support: SR, LD. Analyzed the data: BCA, BD, GD, MS, DV, HKB. Wrote the paper: FD, BCA, BD, SC, HKB. Interpreted the data: all authors. All the authors read and approved the last version of the paper.</p></fn></fn-group><ack><p>We thank patients for having provided tissue and clinical data, and the Plan National Cancer (Belgium) for having supported the project. B. Haibe-Kains was supported by the Gattuso Slaight Personalized Cancer Medicine Fund at Princess Margaret Cancer Centre.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Hal</surname><given-names>NL</given-names></name><name><surname>Vorst</surname><given-names>O</given-names></name><name><surname>van Houwelingen</surname><given-names>AM</given-names></name><name><surname>Kok</surname><given-names>EJ</given-names></name><name><surname>Peijnenburg</surname><given-names>A</given-names></name><name><surname>Aharoni</surname><given-names>A</given-names></name><name><surname>van Tunen</surname><given-names>AJ</given-names></name><name><surname>Keijer</surname><given-names>J</given-names></name></person-group><article-title>The application of DNA microarrays in gene expression analysis</article-title><source>J Biotechnol</source><year>2000</year><volume>78</volume><fpage>271</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1016/S0168-1656(00)00204-2</pub-id><?supplied-pmid 10751688?><pub-id pub-id-type="pmid">10751688</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perou</surname><given-names>CM</given-names></name><name><surname>S&#x000f8;rlie</surname><given-names>T</given-names></name><name><surname>Eisen</surname><given-names>MB</given-names></name><name><surname>van de Rijn</surname><given-names>M</given-names></name><name><surname>Jeffrey</surname><given-names>SS</given-names></name><name><surname>Rees</surname><given-names>CA</given-names></name><name><surname>Pollack</surname><given-names>JR</given-names></name><name><surname>Ross</surname><given-names>DT</given-names></name><name><surname>Johnsen</surname><given-names>H</given-names></name><name><surname>Akslen</surname><given-names>LA</given-names></name><name><surname>Fluge</surname><given-names>O</given-names></name><name><surname>Pergamenschikov</surname><given-names>A</given-names></name><name><surname>Williams</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>SX</given-names></name><name><surname>L&#x000f8;nning</surname><given-names>PE</given-names></name><name><surname>B&#x000f8;rresen-Dale</surname><given-names>AL</given-names></name><name><surname>Brown</surname><given-names>PO</given-names></name><name><surname>Botstein</surname><given-names>D</given-names></name></person-group><article-title>Molecular portraits of human breast tumours</article-title><source>Nature</source><year>2000</year><volume>406</volume><fpage>747</fpage><lpage>752</lpage><pub-id pub-id-type="doi">10.1038/35021093</pub-id><?supplied-pmid 10963602?><pub-id pub-id-type="pmid">10963602</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peppercorn</surname><given-names>J</given-names></name><name><surname>Perou</surname><given-names>CM</given-names></name><name><surname>Carey</surname><given-names>LA</given-names></name></person-group><article-title>Molecular subtypes in breast cancer evaluation and management: divide and conquer</article-title><source>Cancer Invest</source><year>2008</year><volume>26</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1080/07357900701784238</pub-id><?supplied-pmid 18181038?><pub-id pub-id-type="pmid">18181038</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>S&#x000f8;rlie</surname><given-names>T</given-names></name><name><surname>Perou</surname><given-names>CM</given-names></name><name><surname>Tibshirani</surname><given-names>R</given-names></name><name><surname>Aas</surname><given-names>T</given-names></name><name><surname>Geisler</surname><given-names>S</given-names></name><name><surname>Johnsen</surname><given-names>H</given-names></name><name><surname>Hastie</surname><given-names>T</given-names></name><name><surname>Eisen</surname><given-names>MB</given-names></name><name><surname>van de Rijn</surname><given-names>M</given-names></name><name><surname>Jeffrey</surname><given-names>SS</given-names></name><name><surname>Thorsen</surname><given-names>T</given-names></name><name><surname>Quist</surname><given-names>H</given-names></name><name><surname>Matese</surname><given-names>JC</given-names></name><name><surname>Brown</surname><given-names>PO</given-names></name><name><surname>Botstein</surname><given-names>D</given-names></name><name><surname>L&#x000f8;nning</surname><given-names>PE</given-names></name><name><surname>B&#x000f8;rresen-Dale</surname><given-names>AL</given-names></name></person-group><article-title>Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications</article-title><source>Proc Natl Acad Sci U S A</source><year>2001</year><volume>98</volume><fpage>10869</fpage><lpage>10874</lpage><pub-id pub-id-type="doi">10.1073/pnas.191367098</pub-id><?supplied-pmid 11553815?><pub-id pub-id-type="pmid">11553815</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sotiriou</surname><given-names>C</given-names></name><name><surname>Neo</surname><given-names>S-Y</given-names></name><name><surname>McShane</surname><given-names>LM</given-names></name><name><surname>Korn</surname><given-names>EL</given-names></name><name><surname>Long</surname><given-names>PM</given-names></name><name><surname>Jazaeri</surname><given-names>A</given-names></name><name><surname>Martiat</surname><given-names>P</given-names></name><name><surname>Fox</surname><given-names>SB</given-names></name><name><surname>Harris</surname><given-names>AL</given-names></name><name><surname>Liu</surname><given-names>ET</given-names></name></person-group><article-title>Breast cancer classification and prognosis based on gene expression profiles from a population-based study</article-title><source>Proc Natl Acad Sci U S A</source><year>2003</year><volume>100</volume><fpage>10393</fpage><lpage>10398</lpage><pub-id pub-id-type="doi">10.1073/pnas.1732912100</pub-id><?supplied-pmid 12917485?><pub-id pub-id-type="pmid">12917485</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldhirsch</surname><given-names>A</given-names></name><name><surname>Winer</surname><given-names>EP</given-names></name><name><surname>Coates</surname><given-names>AS</given-names></name><name><surname>Gelber</surname><given-names>RD</given-names></name><name><surname>Piccart-Gebhart</surname><given-names>M</given-names></name><name><surname>Th&#x000fc;rlimann</surname><given-names>B</given-names></name><name><surname>Senn</surname><given-names>H-J</given-names></name><collab>Panel members</collab></person-group><article-title>Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International expert consensus on the primary therapy of early breast cancer 2013</article-title><source>Ann Oncol</source><year>2013</year><volume>24</volume><fpage>2206</fpage><lpage>2223</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdt303</pub-id><?supplied-pmid 23917950?><pub-id pub-id-type="pmid">23917950</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desmedt</surname><given-names>C</given-names></name><name><surname>Haibe-Kains</surname><given-names>B</given-names></name><name><surname>Wirapati</surname><given-names>P</given-names></name><name><surname>Buyse</surname><given-names>M</given-names></name><name><surname>Larsimont</surname><given-names>D</given-names></name><name><surname>Bontempi</surname><given-names>G</given-names></name><name><surname>Delorenzi</surname><given-names>M</given-names></name><name><surname>Piccart</surname><given-names>M</given-names></name><name><surname>Sotiriou</surname><given-names>C</given-names></name></person-group><article-title>Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes</article-title><source>Clin Cancer Res</source><year>2008</year><volume>14</volume><fpage>5158</fpage><lpage>5165</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-4756</pub-id><?supplied-pmid 18698033?><pub-id pub-id-type="pmid">18698033</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wirapati</surname><given-names>P</given-names></name><name><surname>Sotiriou</surname><given-names>C</given-names></name><name><surname>Kunkel</surname><given-names>S</given-names></name><name><surname>Farmer</surname><given-names>P</given-names></name><name><surname>Pradervand</surname><given-names>S</given-names></name><name><surname>Haibe-Kains</surname><given-names>B</given-names></name><name><surname>Desmedt</surname><given-names>C</given-names></name><name><surname>Ignatiadis</surname><given-names>M</given-names></name><name><surname>Sengstag</surname><given-names>T</given-names></name><name><surname>Sch&#x000fc;tz</surname><given-names>F</given-names></name><name><surname>Goldstein</surname><given-names>DR</given-names></name><name><surname>Piccart</surname><given-names>M</given-names></name><name><surname>Delorenzi</surname><given-names>M</given-names></name></person-group><article-title>Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures</article-title><source>Breast Cancer Res</source><year>2008</year><volume>10</volume><fpage>R65</fpage><pub-id pub-id-type="doi">10.1186/bcr2124</pub-id><?supplied-pmid 18662380?><pub-id pub-id-type="pmid">18662380</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haibe-Kains</surname><given-names>B</given-names></name><name><surname>Desmedt</surname><given-names>C</given-names></name><name><surname>Loi</surname><given-names>S</given-names></name><name><surname>Culhane</surname><given-names>AC</given-names></name><name><surname>Bontempi</surname><given-names>G</given-names></name><name><surname>Quackenbush</surname><given-names>J</given-names></name><name><surname>Sotiriou</surname><given-names>C</given-names></name></person-group><article-title>A three-gene model to robustly identify breast cancer molecular subtypes</article-title><source>J Natl Cancer Inst</source><year>2012</year><volume>104</volume><fpage>311</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1093/jnci/djr545</pub-id><?supplied-pmid 22262870?><pub-id pub-id-type="pmid">22262870</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorlie</surname><given-names>T</given-names></name><name><surname>Tibshirani</surname><given-names>R</given-names></name><name><surname>Parker</surname><given-names>J</given-names></name><name><surname>Hastie</surname><given-names>T</given-names></name><name><surname>Marron</surname><given-names>JS</given-names></name><name><surname>Nobel</surname><given-names>A</given-names></name><name><surname>Deng</surname><given-names>S</given-names></name><name><surname>Johnsen</surname><given-names>H</given-names></name><name><surname>Pesich</surname><given-names>R</given-names></name><name><surname>Geisler</surname><given-names>S</given-names></name><name><surname>Demeter</surname><given-names>J</given-names></name><name><surname>Perou</surname><given-names>CM</given-names></name><name><surname>L&#x000f8;nning</surname><given-names>PE</given-names></name><name><surname>Brown</surname><given-names>PO</given-names></name><name><surname>B&#x000f8;rresen-Dale</surname><given-names>A-L</given-names></name><name><surname>Botstein</surname><given-names>D</given-names></name></person-group><article-title>Repeated observation of breast tumor subtypes in independent gene expression data sets</article-title><source>Proc Natl Acad Sci U S A</source><year>2003</year><volume>100</volume><fpage>8418</fpage><lpage>8423</lpage><pub-id pub-id-type="doi">10.1073/pnas.0932692100</pub-id><?supplied-pmid 12829800?><pub-id pub-id-type="pmid">12829800</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Fan</surname><given-names>C</given-names></name><name><surname>Oh</surname><given-names>DS</given-names></name><name><surname>Marron</surname><given-names>JS</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Qaqish</surname><given-names>BF</given-names></name><name><surname>Livasy</surname><given-names>C</given-names></name><name><surname>Carey</surname><given-names>LA</given-names></name><name><surname>Reynolds</surname><given-names>E</given-names></name><name><surname>Dressler</surname><given-names>L</given-names></name><name><surname>Nobel</surname><given-names>A</given-names></name><name><surname>Parker</surname><given-names>J</given-names></name><name><surname>Ewend</surname><given-names>MG</given-names></name><name><surname>Sawyer</surname><given-names>LR</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Nanda</surname><given-names>R</given-names></name><name><surname>Tretiakova</surname><given-names>M</given-names></name><name><surname>Ruiz Orrico</surname><given-names>A</given-names></name><name><surname>Dreher</surname><given-names>D</given-names></name><name><surname>Palazzo</surname><given-names>JP</given-names></name><name><surname>Perreard</surname><given-names>L</given-names></name><name><surname>Nelson</surname><given-names>E</given-names></name><name><surname>Mone</surname><given-names>M</given-names></name><name><surname>Hansen</surname><given-names>H</given-names></name><name><surname>Mullins</surname><given-names>M</given-names></name><name><surname>Quackenbush</surname><given-names>JF</given-names></name><name><surname>Ellis</surname><given-names>MJ</given-names></name><name><surname>Olopade</surname><given-names>OI</given-names></name><name><surname>Bernard</surname><given-names>PS</given-names></name><etal/></person-group><article-title>The molecular portraits of breast tumors are conserved across microarray platforms</article-title><source>BMC Genomics</source><year>2006</year><volume>7</volume><fpage>96</fpage><pub-id pub-id-type="doi">10.1186/1471-2164-7-96</pub-id><?supplied-pmid 16643655?><pub-id pub-id-type="pmid">16643655</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parker</surname><given-names>JS</given-names></name><name><surname>Mullins</surname><given-names>M</given-names></name><name><surname>Cheang</surname><given-names>MCU</given-names></name><name><surname>Leung</surname><given-names>S</given-names></name><name><surname>Voduc</surname><given-names>D</given-names></name><name><surname>Vickery</surname><given-names>T</given-names></name><name><surname>Davies</surname><given-names>S</given-names></name><name><surname>Fauron</surname><given-names>C</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Quackenbush</surname><given-names>JF</given-names></name><name><surname>Stijleman</surname><given-names>IJ</given-names></name><name><surname>Palazzo</surname><given-names>J</given-names></name><name><surname>Marron</surname><given-names>JS</given-names></name><name><surname>Nobel</surname><given-names>AB</given-names></name><name><surname>Mardis</surname><given-names>E</given-names></name><name><surname>Nielsen</surname><given-names>TO</given-names></name><name><surname>Ellis</surname><given-names>MJ</given-names></name><name><surname>Perou</surname><given-names>CM</given-names></name><name><surname>Bernard</surname><given-names>PS</given-names></name></person-group><article-title>Supervised risk predictor of breast cancer based on intrinsic subtypes</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><fpage>1160</fpage><lpage>1167</lpage><pub-id pub-id-type="doi">10.1200/JCO.2008.18.1370</pub-id><?supplied-pmid 19204204?><pub-id pub-id-type="pmid">19204204</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other"><italic>Package Insert: Prosigna Breast Cancer Prognostic Gene Signature Assay; Version 01</italic>. 2013. REF LBL-C0223&#x02013;01</mixed-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veer LJ</surname><given-names>V&#x02019;t</given-names></name><name><surname>Dai</surname><given-names>H</given-names></name><name><surname>van de Vijver</surname><given-names>MJ</given-names></name><name><surname>He</surname><given-names>YD</given-names></name><name><surname>Hart</surname><given-names>AAM</given-names></name><name><surname>Mao</surname><given-names>M</given-names></name><name><surname>Peterse</surname><given-names>HL</given-names></name><name><surname>van der Kooy</surname><given-names>K</given-names></name><name><surname>Marton</surname><given-names>MJ</given-names></name><name><surname>Witteveen</surname><given-names>AT</given-names></name><name><surname>Schreiber</surname><given-names>GJ</given-names></name><name><surname>Kerkhoven</surname><given-names>RM</given-names></name><name><surname>Roberts</surname><given-names>C</given-names></name><name><surname>Linsley</surname><given-names>PS</given-names></name><name><surname>Bernards</surname><given-names>R</given-names></name><name><surname>Friend</surname><given-names>SH</given-names></name></person-group><article-title>Gene expression profiling predicts clinical outcome of breast cancer</article-title><source>Nature</source><year>2002</year><volume>415</volume><fpage>530</fpage><lpage>536</lpage><pub-id pub-id-type="doi">10.1038/415530a</pub-id><pub-id pub-id-type="pmid">11823860</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paik</surname><given-names>S</given-names></name><name><surname>Shak</surname><given-names>S</given-names></name><name><surname>Tang</surname><given-names>G</given-names></name><name><surname>Kim</surname><given-names>C</given-names></name><name><surname>Baker</surname><given-names>J</given-names></name><name><surname>Cronin</surname><given-names>M</given-names></name><name><surname>Baehner</surname><given-names>FL</given-names></name><name><surname>Walker</surname><given-names>MG</given-names></name><name><surname>Watson</surname><given-names>D</given-names></name><name><surname>Park</surname><given-names>T</given-names></name><name><surname>Hiller</surname><given-names>W</given-names></name><name><surname>Fisher</surname><given-names>ER</given-names></name><name><surname>Wickerham</surname><given-names>DL</given-names></name><name><surname>Bryant</surname><given-names>J</given-names></name><name><surname>Wolmark</surname><given-names>N</given-names></name></person-group><article-title>A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer</article-title><source>N Engl J Med</source><year>2004</year><volume>351</volume><fpage>2817</fpage><lpage>2826</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa041588</pub-id><?supplied-pmid 15591335?><pub-id pub-id-type="pmid">15591335</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sotiriou</surname><given-names>C</given-names></name><name><surname>Wirapati</surname><given-names>P</given-names></name><name><surname>Loi</surname><given-names>S</given-names></name><name><surname>Harris</surname><given-names>A</given-names></name><name><surname>Fox</surname><given-names>S</given-names></name><name><surname>Smeds</surname><given-names>J</given-names></name><name><surname>Nordgren</surname><given-names>H</given-names></name><name><surname>Farmer</surname><given-names>P</given-names></name><name><surname>Praz</surname><given-names>V</given-names></name><name><surname>Haibe-Kains</surname><given-names>B</given-names></name><name><surname>Desmedt</surname><given-names>C</given-names></name><name><surname>Larsimont</surname><given-names>D</given-names></name><name><surname>Cardoso</surname><given-names>F</given-names></name><name><surname>Peterse</surname><given-names>H</given-names></name><name><surname>Nuyten</surname><given-names>D</given-names></name><name><surname>Buyse</surname><given-names>M</given-names></name><name><surname>Van de Vijver</surname><given-names>MJ</given-names></name><name><surname>Bergh</surname><given-names>J</given-names></name><name><surname>Piccart</surname><given-names>M</given-names></name><name><surname>Delorenzi</surname><given-names>M</given-names></name></person-group><article-title>Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis</article-title><source>J Natl Cancer Inst</source><year>2006</year><volume>98</volume><fpage>262</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1093/jnci/djj052</pub-id><?supplied-pmid 16478745?><pub-id pub-id-type="pmid">16478745</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filipits</surname><given-names>M</given-names></name><name><surname>Rudas</surname><given-names>M</given-names></name><name><surname>Jakesz</surname><given-names>R</given-names></name><name><surname>Dubsky</surname><given-names>P</given-names></name><name><surname>Fitzal</surname><given-names>F</given-names></name><name><surname>Singer</surname><given-names>CF</given-names></name><name><surname>Dietze</surname><given-names>O</given-names></name><name><surname>Greil</surname><given-names>R</given-names></name><name><surname>Jelen</surname><given-names>A</given-names></name><name><surname>Sevelda</surname><given-names>P</given-names></name><name><surname>Freibauer</surname><given-names>C</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>V</given-names></name><name><surname>J&#x000e4;nicke</surname><given-names>F</given-names></name><name><surname>Schmidt</surname><given-names>M</given-names></name><name><surname>K&#x000f6;lbl</surname><given-names>H</given-names></name><name><surname>Rody</surname><given-names>A</given-names></name><name><surname>Kaufmann</surname><given-names>M</given-names></name><name><surname>Schroth</surname><given-names>W</given-names></name><name><surname>Brauch</surname><given-names>H</given-names></name><name><surname>Schwab</surname><given-names>M</given-names></name><name><surname>Fritz</surname><given-names>P</given-names></name><name><surname>Weber</surname><given-names>KE</given-names></name><name><surname>Feder</surname><given-names>IS</given-names></name><name><surname>Hennig</surname><given-names>G</given-names></name><name><surname>Kronenwett</surname><given-names>R</given-names></name><name><surname>Gehrmann</surname><given-names>M</given-names></name><name><surname>Gnant</surname><given-names>M</given-names></name><collab>EP Investigators</collab></person-group><article-title>A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors</article-title><source>Clin Cancer Res</source><year>2011</year><volume>17</volume><fpage>6012</fpage><lpage>6020</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-0926</pub-id><?supplied-pmid 21807638?><pub-id pub-id-type="pmid">21807638</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>SL</given-names></name><name><surname>Eklund</surname><given-names>AC</given-names></name><name><surname>Kohane</surname><given-names>IS</given-names></name><name><surname>Harris</surname><given-names>LN</given-names></name><name><surname>Szallasi</surname><given-names>Z</given-names></name></person-group><article-title>A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers</article-title><source>Nat Genet</source><year>2006</year><volume>38</volume><fpage>1043</fpage><lpage>1048</lpage><pub-id pub-id-type="doi">10.1038/ng1861</pub-id><?supplied-pmid 16921376?><pub-id pub-id-type="pmid">16921376</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teschendorff</surname><given-names>AE</given-names></name><name><surname>Miremadi</surname><given-names>A</given-names></name><name><surname>Pinder</surname><given-names>SE</given-names></name><name><surname>Ellis</surname><given-names>IO</given-names></name><name><surname>Caldas</surname><given-names>C</given-names></name></person-group><article-title>An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer</article-title><source>Genome Biol</source><year>2007</year><volume>8</volume><fpage>R157</fpage><pub-id pub-id-type="doi">10.1186/gb-2007-8-8-r157</pub-id><?supplied-pmid 17683518?><pub-id pub-id-type="pmid">17683518</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farmer</surname><given-names>P</given-names></name><name><surname>Bonnefoi</surname><given-names>H</given-names></name><name><surname>Anderle</surname><given-names>P</given-names></name><name><surname>Cameron</surname><given-names>D</given-names></name><name><surname>Wirapati</surname><given-names>P</given-names></name><name><surname>Wirapati</surname><given-names>P</given-names></name><name><surname>Becette</surname><given-names>V</given-names></name><name><surname>Andr&#x000e9;</surname><given-names>S</given-names></name><name><surname>Piccart</surname><given-names>M</given-names></name><name><surname>Campone</surname><given-names>M</given-names></name><name><surname>Brain</surname><given-names>E</given-names></name><name><surname>Macgrogan</surname><given-names>G</given-names></name><name><surname>Petit</surname><given-names>T</given-names></name><name><surname>Jassem</surname><given-names>J</given-names></name><name><surname>Bibeau</surname><given-names>F</given-names></name><name><surname>Blot</surname><given-names>E</given-names></name><name><surname>Bogaerts</surname><given-names>J</given-names></name><name><surname>Aguet</surname><given-names>M</given-names></name><name><surname>Bergh</surname><given-names>J</given-names></name><name><surname>Iggo</surname><given-names>R</given-names></name><name><surname>Delorenzi</surname><given-names>M</given-names></name></person-group><article-title>A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer</article-title><source>Nat Med</source><year>2009</year><volume>15</volume><fpage>68</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1038/nm.1908</pub-id><?supplied-pmid 19122658?><pub-id pub-id-type="pmid">19122658</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desmedt</surname><given-names>C</given-names></name><name><surname>Majjaj</surname><given-names>S</given-names></name><name><surname>Kheddoumi</surname><given-names>N</given-names></name><name><surname>Singhal</surname><given-names>SK</given-names></name><name><surname>Haibe-Kains</surname><given-names>B</given-names></name><name><surname>El Ouriaghli</surname><given-names>F</given-names></name><name><surname>Chaboteaux</surname><given-names>C</given-names></name><name><surname>Michiels</surname><given-names>S</given-names></name><name><surname>Lallemand</surname><given-names>F</given-names></name><name><surname>Journe</surname><given-names>F</given-names></name><name><surname>Duvillier</surname><given-names>H</given-names></name><name><surname>Loi</surname><given-names>S</given-names></name><name><surname>Quackenbush</surname><given-names>J</given-names></name><name><surname>Dekoninck</surname><given-names>S</given-names></name><name><surname>Blanpain</surname><given-names>C</given-names></name><name><surname>Lagneaux</surname><given-names>L</given-names></name><name><surname>Houhou</surname><given-names>N</given-names></name><name><surname>Delorenzi</surname><given-names>M</given-names></name><name><surname>Larsimont</surname><given-names>D</given-names></name><name><surname>Piccart</surname><given-names>M</given-names></name><name><surname>Sotiriou</surname><given-names>C</given-names></name></person-group><article-title>Characterization and clinical evaluation of CD10+ stroma cells in the breast cancer microenvironment</article-title><source>Clin Cancer Res</source><year>2012</year><volume>18</volume><fpage>1004</fpage><lpage>1014</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-0383</pub-id><?supplied-pmid 22235100?><pub-id pub-id-type="pmid">22235100</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loi</surname><given-names>S</given-names></name><name><surname>Haibe-Kains</surname><given-names>B</given-names></name><name><surname>Majjaj</surname><given-names>S</given-names></name><name><surname>Lallemand</surname><given-names>F</given-names></name><name><surname>Durbecq</surname><given-names>V</given-names></name><name><surname>Larsimont</surname><given-names>D</given-names></name><name><surname>Gonzalez-Angulo</surname><given-names>AM</given-names></name><name><surname>Pusztai</surname><given-names>L</given-names></name><name><surname>Symmans</surname><given-names>WF</given-names></name><name><surname>Bardelli</surname><given-names>A</given-names></name><name><surname>Ellis</surname><given-names>P</given-names></name><name><surname>Tutt</surname><given-names>ANJ</given-names></name><name><surname>Gillett</surname><given-names>CE</given-names></name><name><surname>Hennessy</surname><given-names>BT</given-names></name><name><surname>Mills</surname><given-names>GB</given-names></name><name><surname>Phillips</surname><given-names>WA</given-names></name><name><surname>Piccart</surname><given-names>MJ</given-names></name><name><surname>Speed</surname><given-names>TP</given-names></name><name><surname>McArthur</surname><given-names>GA</given-names></name><name><surname>Sotiriou</surname><given-names>C</given-names></name></person-group><article-title>PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer</article-title><source>Proc Natl Acad Sci U S A</source><year>2010</year><volume>107</volume><fpage>10208</fpage><lpage>10213</lpage><pub-id pub-id-type="doi">10.1073/pnas.0907011107</pub-id><?supplied-pmid 20479250?><pub-id pub-id-type="pmid">20479250</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saal</surname><given-names>LH</given-names></name><name><surname>Johansson</surname><given-names>P</given-names></name><name><surname>Holm</surname><given-names>K</given-names></name><name><surname>Gruvberger-Saal</surname><given-names>SK</given-names></name><name><surname>She</surname><given-names>Q-B</given-names></name><name><surname>Maurer</surname><given-names>M</given-names></name><name><surname>Koujak</surname><given-names>S</given-names></name><name><surname>Ferrando</surname><given-names>AA</given-names></name><name><surname>Malmstr&#x000f6;m</surname><given-names>P</given-names></name><name><surname>Memeo</surname><given-names>L</given-names></name><name><surname>Isola</surname><given-names>J</given-names></name><name><surname>Bendahl</surname><given-names>P-O</given-names></name><name><surname>Rosen</surname><given-names>N</given-names></name><name><surname>Hibshoosh</surname><given-names>H</given-names></name><name><surname>Ringn&#x000e9;r</surname><given-names>M</given-names></name><name><surname>Borg</surname><given-names>A</given-names></name><name><surname>Parsons</surname><given-names>R</given-names></name></person-group><article-title>Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity</article-title><source>Proc Natl Acad Sci U S A</source><year>2007</year><volume>104</volume><fpage>7564</fpage><lpage>7569</lpage><pub-id pub-id-type="doi">10.1073/pnas.0702507104</pub-id><?supplied-pmid 17452630?><pub-id pub-id-type="pmid">17452630</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Creighton</surname><given-names>CJ</given-names></name><name><surname>Casa</surname><given-names>A</given-names></name><name><surname>Lazard</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Tsimelzon</surname><given-names>A</given-names></name><name><surname>Hilsenbeck</surname><given-names>SG</given-names></name><name><surname>Osborne</surname><given-names>CK</given-names></name><name><surname>Lee</surname><given-names>AV</given-names></name></person-group><article-title>Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>4078</fpage><lpage>4085</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.13.4429</pub-id><?supplied-pmid 18757322?><pub-id pub-id-type="pmid">18757322</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Majumder</surname><given-names>PK</given-names></name><name><surname>Febbo</surname><given-names>PG</given-names></name><name><surname>Bikoff</surname><given-names>R</given-names></name><name><surname>Berger</surname><given-names>R</given-names></name><name><surname>Xue</surname><given-names>Q</given-names></name><name><surname>McMahon</surname><given-names>LM</given-names></name><name><surname>Manola</surname><given-names>J</given-names></name><name><surname>Brugarolas</surname><given-names>J</given-names></name><name><surname>McDonnell</surname><given-names>TJ</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Loda</surname><given-names>M</given-names></name><name><surname>Lane</surname><given-names>HA</given-names></name><name><surname>Sellers</surname><given-names>WR</given-names></name></person-group><article-title>mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways</article-title><source>Nat Med</source><year>2004</year><volume>10</volume><fpage>594</fpage><lpage>601</lpage><pub-id pub-id-type="doi">10.1038/nm1052</pub-id><?supplied-pmid 15156201?><pub-id pub-id-type="pmid">15156201</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Creighton</surname><given-names>CJ</given-names></name><name><surname>Hilger</surname><given-names>AM</given-names></name><name><surname>Murthy</surname><given-names>S</given-names></name><name><surname>Rae</surname><given-names>JM</given-names></name><name><surname>Chinnaiyan</surname><given-names>AM</given-names></name><name><surname>El-Ashry</surname><given-names>D</given-names></name></person-group><article-title>Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors</article-title><source>Cancer Res</source><year>2006</year><volume>66</volume><fpage>3903</fpage><lpage>3911</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-4363</pub-id><?supplied-pmid 16585219?><pub-id pub-id-type="pmid">16585219</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bild</surname><given-names>AH</given-names></name><name><surname>Yao</surname><given-names>G</given-names></name><name><surname>Chang</surname><given-names>JT</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Potti</surname><given-names>A</given-names></name><name><surname>Chasse</surname><given-names>D</given-names></name><name><surname>Joshi</surname><given-names>M-B</given-names></name><name><surname>Harpole</surname><given-names>D</given-names></name><name><surname>Lancaster</surname><given-names>JM</given-names></name><name><surname>Berchuck</surname><given-names>A</given-names></name><name><surname>Olson</surname><given-names>JA</given-names><suffix>Jr</suffix></name><name><surname>Marks</surname><given-names>JR</given-names></name><name><surname>Dressman</surname><given-names>HK</given-names></name><name><surname>West</surname><given-names>M</given-names></name><name><surname>Nevins</surname><given-names>JR</given-names></name></person-group><article-title>Oncogenic pathway signatures in human cancers as a guide to targeted therapies</article-title><source>Nature</source><year>2006</year><volume>439</volume><fpage>353</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1038/nature04296</pub-id><?supplied-pmid 16273092?><pub-id pub-id-type="pmid">16273092</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mortazavi</surname><given-names>A</given-names></name><name><surname>Williams</surname><given-names>BA</given-names></name><name><surname>McCue</surname><given-names>K</given-names></name><name><surname>Schaeffer</surname><given-names>L</given-names></name><name><surname>Wold</surname><given-names>B</given-names></name></person-group><article-title>Mapping and quantifying mammalian transcriptomes by RNA-Seq</article-title><source>Nat Methods</source><year>2008</year><volume>5</volume><fpage>621</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1226</pub-id><?supplied-pmid 18516045?><pub-id pub-id-type="pmid">18516045</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sultan</surname><given-names>M</given-names></name><name><surname>Schulz</surname><given-names>MH</given-names></name><name><surname>Richard</surname><given-names>H</given-names></name><name><surname>Magen</surname><given-names>A</given-names></name><name><surname>Klingenhoff</surname><given-names>A</given-names></name><name><surname>Scherf</surname><given-names>M</given-names></name><name><surname>Seifert</surname><given-names>M</given-names></name><name><surname>Borodina</surname><given-names>T</given-names></name><name><surname>Soldatov</surname><given-names>A</given-names></name><name><surname>Parkhomchuk</surname><given-names>D</given-names></name><name><surname>Schmidt</surname><given-names>D</given-names></name><name><surname>O&#x02019;Keeffe</surname><given-names>S</given-names></name><name><surname>Haas</surname><given-names>S</given-names></name><name><surname>Vingron</surname><given-names>M</given-names></name><name><surname>Lehrach</surname><given-names>H</given-names></name><name><surname>Yaspo</surname><given-names>M-L</given-names></name></person-group><article-title>A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome</article-title><source>Science</source><year>2008</year><volume>321</volume><fpage>956</fpage><lpage>960</lpage><pub-id pub-id-type="doi">10.1126/science.1160342</pub-id><?supplied-pmid 18599741?><pub-id pub-id-type="pmid">18599741</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Gerstein</surname><given-names>M</given-names></name><name><surname>Snyder</surname><given-names>M</given-names></name></person-group><article-title>RNA-Seq: a revolutionary tool for transcriptomics</article-title><source>Nat Rev Genet</source><year>2009</year><volume>10</volume><fpage>57</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1038/nrg2484</pub-id><?supplied-pmid 19015660?><pub-id pub-id-type="pmid">19015660</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozsolak</surname><given-names>F</given-names></name><name><surname>Milos</surname><given-names>PM</given-names></name></person-group><article-title>RNA sequencing: advances, challenges and opportunities</article-title><source>Nat Rev Genet</source><year>2011</year><volume>12</volume><fpage>87</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1038/nrg2934</pub-id><?supplied-pmid 21191423?><pub-id pub-id-type="pmid">21191423</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malone</surname><given-names>JH</given-names></name><name><surname>Oliver</surname><given-names>B</given-names></name></person-group><article-title>Microarrays, deep sequencing and the true measure of the transcriptome</article-title><source>BMC Biol</source><year>2011</year><volume>9</volume><fpage>34</fpage><pub-id pub-id-type="doi">10.1186/1741-7007-9-34</pub-id><?supplied-pmid 21627854?><pub-id pub-id-type="pmid">21627854</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagalakshmi</surname><given-names>U</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Waern</surname><given-names>K</given-names></name><name><surname>Shou</surname><given-names>C</given-names></name><name><surname>Raha</surname><given-names>D</given-names></name><name><surname>Gerstein</surname><given-names>M</given-names></name><name><surname>Snyder</surname><given-names>M</given-names></name></person-group><article-title>The transcriptional landscape of the yeast genome defined by RNA sequencing</article-title><source>Science</source><year>2008</year><volume>320</volume><fpage>1344</fpage><lpage>1349</lpage><pub-id pub-id-type="doi">10.1126/science.1158441</pub-id><?supplied-pmid 18451266?><pub-id pub-id-type="pmid">18451266</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marioni</surname><given-names>JC</given-names></name><name><surname>Mason</surname><given-names>CE</given-names></name><name><surname>Mane</surname><given-names>SM</given-names></name><name><surname>Stephens</surname><given-names>M</given-names></name><name><surname>Gilad</surname><given-names>Y</given-names></name></person-group><article-title>RNA-seq: an assessment of technical reproducibility and comparison with gene expression arrays</article-title><source>Genome Res</source><year>2008</year><volume>18</volume><fpage>1509</fpage><lpage>1517</lpage><pub-id pub-id-type="doi">10.1101/gr.079558.108</pub-id><?supplied-pmid 18550803?><pub-id pub-id-type="pmid">18550803</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>X</given-names></name><name><surname>Fu</surname><given-names>N</given-names></name><name><surname>Guo</surname><given-names>S</given-names></name><name><surname>Yan</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Menzel</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zeng</surname><given-names>R</given-names></name><name><surname>Khaitovich</surname><given-names>P</given-names></name></person-group><article-title>Estimating accuracy of RNA-Seq and microarrays with proteomics</article-title><source>BMC Genomics</source><year>2009</year><volume>10</volume><fpage>161</fpage><pub-id pub-id-type="doi">10.1186/1471-2164-10-161</pub-id><?supplied-pmid 19371429?><pub-id pub-id-type="pmid">19371429</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montgomery</surname><given-names>SB</given-names></name><name><surname>Sammeth</surname><given-names>M</given-names></name><name><surname>Gutierrez-Arcelus</surname><given-names>M</given-names></name><name><surname>Lach</surname><given-names>RP</given-names></name><name><surname>Ingle</surname><given-names>C</given-names></name><name><surname>Nisbett</surname><given-names>J</given-names></name><name><surname>Guigo</surname><given-names>R</given-names></name><name><surname>Dermitzakis</surname><given-names>ET</given-names></name></person-group><article-title>Transcriptome genetics using second generation sequencing in a Caucasian population</article-title><source>Nature</source><year>2010</year><volume>464</volume><fpage>773</fpage><lpage>777</lpage><pub-id pub-id-type="doi">10.1038/nature08903</pub-id><?supplied-pmid 20220756?><pub-id pub-id-type="pmid">20220756</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pickrell</surname><given-names>JK</given-names></name><name><surname>Marioni</surname><given-names>JC</given-names></name><name><surname>Pai</surname><given-names>AA</given-names></name><name><surname>Degner</surname><given-names>JF</given-names></name><name><surname>Engelhardt</surname><given-names>BE</given-names></name><name><surname>Nkadori</surname><given-names>E</given-names></name><name><surname>Veyrieras</surname><given-names>J-B</given-names></name><name><surname>Stephens</surname><given-names>M</given-names></name><name><surname>Gilad</surname><given-names>Y</given-names></name><name><surname>Pritchard</surname><given-names>JK</given-names></name></person-group><article-title>Understanding mechanisms underlying human gene expression variation with RNA sequencing</article-title><source>Nature</source><year>2010</year><volume>464</volume><fpage>768</fpage><lpage>772</lpage><pub-id pub-id-type="doi">10.1038/nature08872</pub-id><?supplied-pmid 20220758?><pub-id pub-id-type="pmid">20220758</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bradford</surname><given-names>JR</given-names></name><name><surname>Hey</surname><given-names>Y</given-names></name><name><surname>Yates</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Pepper</surname><given-names>SD</given-names></name><name><surname>Miller</surname><given-names>CJ</given-names></name></person-group><article-title>A comparison of massively parallel nucleotide sequencing with oligonucleotide microarrays for global transcription profiling</article-title><source>BMC Genomics</source><year>2010</year><volume>11</volume><fpage>282</fpage><pub-id pub-id-type="doi">10.1186/1471-2164-11-282</pub-id><?supplied-pmid 20444259?><pub-id pub-id-type="pmid">20444259</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Jiang</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Xing</surname><given-names>Y</given-names></name></person-group><article-title>A comparison of RNA-Seq and high-density exon array for detecting differential gene expression between closely related species</article-title><source>Nucleic Acids Res</source><year>2011</year><volume>39</volume><fpage>578</fpage><lpage>588</lpage><pub-id pub-id-type="doi">10.1093/nar/gkq817</pub-id><?supplied-pmid 20864445?><pub-id pub-id-type="pmid">20864445</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nookaew</surname><given-names>I</given-names></name><name><surname>Papini</surname><given-names>M</given-names></name><name><surname>Pornputtapong</surname><given-names>N</given-names></name><name><surname>Scalcinati</surname><given-names>G</given-names></name><name><surname>Fagerberg</surname><given-names>L</given-names></name><name><surname>Uhl&#x000e9;n</surname><given-names>M</given-names></name><name><surname>Nielsen</surname><given-names>J</given-names></name></person-group><article-title>A comprehensive comparison of RNA-Seq-based transcriptome analysis from reads to differential gene expression and cross-comparison with microarrays: a case study in Saccharomyces cerevisiae</article-title><source>Nucleic Acids Res</source><year>2012</year><volume>40</volume><fpage>10084</fpage><lpage>10097</lpage><pub-id pub-id-type="doi">10.1093/nar/gks804</pub-id><?supplied-pmid 22965124?><pub-id pub-id-type="pmid">22965124</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sekhon</surname><given-names>RS</given-names></name><name><surname>Briskine</surname><given-names>R</given-names></name><name><surname>Hirsch</surname><given-names>CN</given-names></name><name><surname>Myers</surname><given-names>CL</given-names></name><name><surname>Springer</surname><given-names>NM</given-names></name><name><surname>Buell</surname><given-names>CR</given-names></name><name><surname>de Leon</surname><given-names>N</given-names></name><name><surname>Kaeppler</surname><given-names>SM</given-names></name></person-group><article-title>Maize gene atlas developed by RNA sequencing and comparative evaluation of transcriptomes based on RNA sequencing and microarrays</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e61005</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0061005</pub-id><?supplied-pmid 23637782?><pub-id pub-id-type="pmid">23637782</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Williams</surname><given-names>J</given-names></name><name><surname>Antoniou</surname><given-names>E</given-names></name><name><surname>McCombie</surname><given-names>WR</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Davidson</surname><given-names>NO</given-names></name><name><surname>Denoya</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>E</given-names></name></person-group><article-title>Parallel comparison of Illumina RNA-Seq and Affymetrix microarray platforms on transcriptomic profiles generated from 5-aza-deoxy-cytidine treated HT-29 colon cancer cells and simulated datasets</article-title><source>BMC Bioinformatics</source><year>2013</year><volume>14</volume><issue>Suppl 9</issue><fpage>S1</fpage><pub-id pub-id-type="doi">10.1186/1471-2105-14-S9-S1</pub-id><?supplied-pmid 23902433?><pub-id pub-id-type="pmid">23902433</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sotiriou</surname><given-names>C</given-names></name><name><surname>Pusztai</surname><given-names>L</given-names></name></person-group><article-title>Gene-expression signatures in breast cancer</article-title><source>N Engl J Med</source><year>2009</year><volume>360</volume><fpage>790</fpage><lpage>800</lpage><pub-id pub-id-type="doi">10.1056/NEJMra0801289</pub-id><?supplied-pmid 19228622?><pub-id pub-id-type="pmid">19228622</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><mixed-citation publication-type="other"><bold>ArrayAnalysis.org</bold>. <ext-link ext-link-type="uri" xlink:href="http://www.arrayanalysis.org/">http://www.arrayanalysis.org/</ext-link></mixed-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCall</surname><given-names>MN</given-names></name><name><surname>Bolstad</surname><given-names>BM</given-names></name><name><surname>Irizarry</surname><given-names>RA</given-names></name></person-group><article-title>Frozen robust multiarray analysis (fRMA)</article-title><source>Biostatistics</source><year>2010</year><volume>11</volume><fpage>242</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1093/biostatistics/kxp059</pub-id><?supplied-pmid 20097884?><pub-id pub-id-type="pmid">20097884</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>R Development Core Team</collab></person-group><source>R: A Language and Environment for Statistical Computing</source><year>2011</year></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Birkbak</surname><given-names>NJ</given-names></name><name><surname>Gyorffy</surname><given-names>B</given-names></name><name><surname>Szallasi</surname><given-names>Z</given-names></name><name><surname>Eklund</surname><given-names>AC</given-names></name></person-group><article-title>Jetset: selecting the optimal microarray probe set to represent a gene</article-title><source>BMC Bioinformatics</source><year>2011</year><volume>12</volume><fpage>474</fpage><pub-id pub-id-type="doi">10.1186/1471-2105-12-474</pub-id><?supplied-pmid 22172014?><pub-id pub-id-type="pmid">22172014</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durinck</surname><given-names>S</given-names></name><name><surname>Moreau</surname><given-names>Y</given-names></name><name><surname>Kasprzyk</surname><given-names>A</given-names></name><name><surname>Davis</surname><given-names>S</given-names></name><name><surname>De Moor</surname><given-names>B</given-names></name><name><surname>Brazma</surname><given-names>A</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name></person-group><article-title>BioMart and Bioconductor: a powerful link between biological databases and microarray data analysis</article-title><source>Bioinformatics</source><year>2005</year><volume>21</volume><fpage>3439</fpage><lpage>3440</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bti525</pub-id><?supplied-pmid 16082012?><pub-id pub-id-type="pmid">16082012</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><mixed-citation publication-type="other"><bold>European Genome-phenome Archive</bold>. <ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/ega">https://www.ebi.ac.uk/ega</ext-link></mixed-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Andrews</surname><given-names>S</given-names></name></person-group><source>FastQC A Quality Control tool for High Throughput Sequence Data</source><year>2014</year></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnett</surname><given-names>DW</given-names></name><name><surname>Garrison</surname><given-names>EK</given-names></name><name><surname>Quinlan</surname><given-names>AR</given-names></name><name><surname>Str&#x000f6;mberg</surname><given-names>MP</given-names></name><name><surname>Marth</surname><given-names>GT</given-names></name></person-group><article-title>BamTools: a C++ API and toolkit for analyzing and managing BAM files</article-title><source>Bioinformatics</source><year>2011</year><volume>27</volume><fpage>1691</fpage><lpage>1692</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btr174</pub-id><?supplied-pmid 21493652?><pub-id pub-id-type="pmid">21493652</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><mixed-citation publication-type="other"><bold>Picard</bold> 2014.<ext-link ext-link-type="uri" xlink:href="http://picard.sourceforge.net">http://picard.sourceforge.net</ext-link></mixed-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garber</surname><given-names>M</given-names></name><name><surname>Grabherr</surname><given-names>MG</given-names></name><name><surname>Guttman</surname><given-names>M</given-names></name><name><surname>Trapnell</surname><given-names>C</given-names></name></person-group><article-title>Computational methods for transcriptome annotation and quantification using RNA-seq</article-title><source>Nat Methods</source><year>2011</year><volume>8</volume><fpage>469</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1613</pub-id><?supplied-pmid 21623353?><pub-id pub-id-type="pmid">21623353</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><mixed-citation publication-type="other"><bold>Bioconductor-genefu</bold>. <ext-link ext-link-type="uri" xlink:href="http://www.bioconductor.org/packages/release/bioc/html/genefu.html">http://www.bioconductor.org/packages/release/bioc/html/genefu.html</ext-link></mixed-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ignatiadis</surname><given-names>M</given-names></name><name><surname>Singhal</surname><given-names>SK</given-names></name><name><surname>Desmedt</surname><given-names>C</given-names></name><name><surname>Haibe-Kains</surname><given-names>B</given-names></name><name><surname>Criscitiello</surname><given-names>C</given-names></name><name><surname>Andre</surname><given-names>F</given-names></name><name><surname>Loi</surname><given-names>S</given-names></name><name><surname>Piccart</surname><given-names>M</given-names></name><name><surname>Michiels</surname><given-names>S</given-names></name><name><surname>Sotiriou</surname><given-names>C</given-names></name></person-group><article-title>Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis</article-title><source>J Clin Oncol</source><year>2012</year><volume>30</volume><fpage>1996</fpage><lpage>2004</lpage><pub-id pub-id-type="doi">10.1200/JCO.2011.39.5624</pub-id><?supplied-pmid 22508827?><pub-id pub-id-type="pmid">22508827</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Culhane</surname><given-names>AC</given-names></name><name><surname>Schr&#x000f6;der</surname><given-names>MS</given-names></name><name><surname>Sultana</surname><given-names>R</given-names></name><name><surname>Picard</surname><given-names>SC</given-names></name><name><surname>Martinelli</surname><given-names>EN</given-names></name><name><surname>Kelly</surname><given-names>C</given-names></name><name><surname>Haibe-Kains</surname><given-names>B</given-names></name><name><surname>Kapushesky</surname><given-names>M</given-names></name><name><surname>St Pierre</surname><given-names>A-A</given-names></name><name><surname>Flahive</surname><given-names>W</given-names></name><name><surname>Picard</surname><given-names>KC</given-names></name><name><surname>Gusenleitner</surname><given-names>D</given-names></name><name><surname>Papenhausen</surname><given-names>G</given-names></name><name><surname>O&#x02019;Connor</surname><given-names>N</given-names></name><name><surname>Correll</surname><given-names>M</given-names></name><name><surname>Quackenbush</surname><given-names>J</given-names></name></person-group><article-title>GeneSigDB: a manually curated database and resource for analysis of gene expression signatures</article-title><source>Nucleic Acids Res</source><year>2012</year><volume>40</volume><issue>Database issue</issue><fpage>D1060</fpage><lpage>D1066</lpage><pub-id pub-id-type="doi">10.1093/nar/gkr901</pub-id><?supplied-pmid 22110038?><pub-id pub-id-type="pmid">22110038</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gentleman</surname><given-names>R</given-names></name></person-group><article-title>Reproducible research: a bioinformatics case study</article-title><source>Stat Appl Genet Mol Biol</source><year>2005</year><volume>4</volume><fpage>1544</fpage><lpage>6115</lpage></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramaniam</surname><given-names>S</given-names></name><name><surname>Hsiao</surname><given-names>G</given-names></name></person-group><article-title>Gene-expression measurement: variance-modeling considerations for robust data analysis</article-title><source>Nat Immunol</source><year>2012</year><volume>13</volume><fpage>199</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1038/ni.2244</pub-id><?supplied-pmid 22344273?><pub-id pub-id-type="pmid">22344273</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>L</given-names></name><name><surname>Fritsche</surname><given-names>H</given-names></name><name><surname>Mennel</surname><given-names>R</given-names></name><name><surname>Norton</surname><given-names>L</given-names></name><name><surname>Ravdin</surname><given-names>P</given-names></name><name><surname>Taube</surname><given-names>S</given-names></name><name><surname>Somerfield</surname><given-names>MR</given-names></name><name><surname>Hayes</surname><given-names>DF</given-names></name><name><surname>Bast</surname><given-names>RC</given-names><suffix>Jr</suffix></name><collab>American Society of Clinical Oncology</collab></person-group><article-title>American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><fpage>5287</fpage><lpage>5312</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.14.2364</pub-id><?supplied-pmid 17954709?><pub-id pub-id-type="pmid">17954709</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hammond</surname><given-names>MEH</given-names></name><name><surname>Hayes</surname><given-names>DF</given-names></name><name><surname>Dowsett</surname><given-names>M</given-names></name><name><surname>Allred</surname><given-names>DC</given-names></name><name><surname>Hagerty</surname><given-names>KL</given-names></name><name><surname>Badve</surname><given-names>S</given-names></name><name><surname>Fitzgibbons</surname><given-names>PL</given-names></name><name><surname>Francis</surname><given-names>G</given-names></name><name><surname>Goldstein</surname><given-names>NS</given-names></name><name><surname>Hayes</surname><given-names>M</given-names></name><name><surname>Hicks</surname><given-names>DG</given-names></name><name><surname>Lester</surname><given-names>S</given-names></name><name><surname>Love</surname><given-names>R</given-names></name><name><surname>Mangu</surname><given-names>PB</given-names></name><name><surname>McShane</surname><given-names>L</given-names></name><name><surname>Miller</surname><given-names>K</given-names></name><name><surname>Osborne</surname><given-names>CK</given-names></name><name><surname>Paik</surname><given-names>S</given-names></name><name><surname>Perlmutter</surname><given-names>J</given-names></name><name><surname>Rhodes</surname><given-names>A</given-names></name><name><surname>Sasano</surname><given-names>H</given-names></name><name><surname>Schwartz</surname><given-names>JN</given-names></name><name><surname>Sweep</surname><given-names>FCG</given-names></name><name><surname>Taube</surname><given-names>S</given-names></name><name><surname>Torlakovic</surname><given-names>EE</given-names></name><name><surname>Valenstein</surname><given-names>P</given-names></name><name><surname>Viale</surname><given-names>G</given-names></name><name><surname>Visscher</surname><given-names>D</given-names></name><name><surname>Wheeler</surname><given-names>T</given-names></name><name><surname>Williams</surname><given-names>RB</given-names></name><etal/></person-group><article-title>American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version)</article-title><source>Arch Pathol Lab Med</source><year>2010</year><volume>134</volume><fpage>e48</fpage><lpage>e72</lpage><?supplied-pmid 20586616?><pub-id pub-id-type="pmid">20586616</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolff</surname><given-names>AC</given-names></name><name><surname>Hammond</surname><given-names>MEH</given-names></name><name><surname>Hicks</surname><given-names>DG</given-names></name><name><surname>Dowsett</surname><given-names>M</given-names></name><name><surname>McShane</surname><given-names>LM</given-names></name><name><surname>Allison</surname><given-names>KH</given-names></name><name><surname>Allred</surname><given-names>DC</given-names></name><name><surname>Bartlett</surname><given-names>JMS</given-names></name><name><surname>Bilous</surname><given-names>M</given-names></name><name><surname>Fitzgibbons</surname><given-names>P</given-names></name><name><surname>Hanna</surname><given-names>W</given-names></name><name><surname>Jenkins</surname><given-names>RB</given-names></name><name><surname>Mangu</surname><given-names>PB</given-names></name><name><surname>Paik</surname><given-names>S</given-names></name><name><surname>Perez</surname><given-names>EA</given-names></name><name><surname>Press</surname><given-names>MF</given-names></name><name><surname>Spears</surname><given-names>PA</given-names></name><name><surname>Vance</surname><given-names>GH</given-names></name><name><surname>Viale</surname><given-names>G</given-names></name><name><surname>Hayes</surname><given-names>DF</given-names></name></person-group><article-title>Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/College of American Pathologists clinical practice guideline update</article-title><source>Arch Pathol Lab Med</source><year>2014</year><volume>138</volume><fpage>241</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.5858/arpa.2013-0953-SA</pub-id><?supplied-pmid 24099077?><pub-id pub-id-type="pmid">24099077</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cardoso</surname><given-names>F</given-names></name><name><surname>Van&#x02019;t Veer</surname><given-names>L</given-names></name><name><surname>Rutgers</surname><given-names>E</given-names></name><name><surname>Loi</surname><given-names>S</given-names></name><name><surname>Mook</surname><given-names>S</given-names></name><name><surname>Piccart-Gebhart</surname><given-names>MJ</given-names></name></person-group><article-title>Clinical application of the 70-gene profile: the MINDACT trial</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>729</fpage><lpage>735</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.14.3222</pub-id><?supplied-pmid 18258980?><pub-id pub-id-type="pmid">18258980</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sparano</surname><given-names>JA</given-names></name></person-group><article-title>TAILORx: trial assigning individualized options for treatment (Rx)</article-title><source>Clin Breast Cancer</source><year>2006</year><volume>7</volume><fpage>347</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.3816/CBC.2006.n.051</pub-id><?supplied-pmid 17092406?><pub-id pub-id-type="pmid">17092406</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Reid</surname><given-names>LH</given-names></name><name><surname>Jones</surname><given-names>WD</given-names></name><name><surname>Shippy</surname><given-names>R</given-names></name><name><surname>Warrington</surname><given-names>JA</given-names></name><name><surname>Baker</surname><given-names>SC</given-names></name><name><surname>Collins</surname><given-names>PJ</given-names></name><name><surname>de Longueville</surname><given-names>F</given-names></name><name><surname>Kawasaki</surname><given-names>ES</given-names></name><name><surname>Lee</surname><given-names>KY</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>YA</given-names></name><name><surname>Willey</surname><given-names>JC</given-names></name><name><surname>Setterquist</surname><given-names>RA</given-names></name><name><surname>Fischer</surname><given-names>GM</given-names></name><name><surname>Tong</surname><given-names>W</given-names></name><name><surname>Dragan</surname><given-names>YP</given-names></name><name><surname>Dix</surname><given-names>DJ</given-names></name><name><surname>Frueh</surname><given-names>FW</given-names></name><name><surname>Goodsaid</surname><given-names>FM</given-names></name><name><surname>Herman</surname><given-names>D</given-names></name><name><surname>Jensen</surname><given-names>RV</given-names></name><name><surname>Johnson</surname><given-names>CD</given-names></name><name><surname>Lobenhofer</surname><given-names>EK</given-names></name><name><surname>Puri</surname><given-names>RK</given-names></name><name><surname>Schrf</surname><given-names>U</given-names></name><name><surname>Thierry-Mieg</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Wilson</surname><given-names>M</given-names></name><collab>MAQC Consortium</collab><etal/></person-group><article-title>The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements</article-title><source>Nat Biotechnol</source><year>2006</year><volume>24</volume><fpage>1151</fpage><lpage>1161</lpage><pub-id pub-id-type="doi">10.1038/nbt1239</pub-id><?supplied-pmid 16964229?><pub-id pub-id-type="pmid">16964229</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Sheng</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Ye</surname><given-names>F</given-names></name><name><surname>Samuels</surname><given-names>DC</given-names></name><name><surname>Shyr</surname><given-names>Y</given-names></name></person-group><article-title>Large scale comparison of gene expression levels by microarrays and RNAseq using TCGA data</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e71462</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0071462</pub-id><?supplied-pmid 23977046?><pub-id pub-id-type="pmid">23977046</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roepman</surname><given-names>P</given-names></name><name><surname>Horlings</surname><given-names>HM</given-names></name><name><surname>Krijgsman</surname><given-names>O</given-names></name><name><surname>Kok</surname><given-names>M</given-names></name><name><surname>Bueno-de-Mesquita</surname><given-names>JM</given-names></name><name><surname>Bender</surname><given-names>R</given-names></name><name><surname>Linn</surname><given-names>SC</given-names></name><name><surname>Glas</surname><given-names>AM</given-names></name><name><surname>van de Vijver</surname><given-names>MJ</given-names></name></person-group><article-title>Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer</article-title><source>Clin Cancer Res</source><year>2009</year><volume>15</volume><fpage>7003</fpage><lpage>7011</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-09-0449</pub-id><?supplied-pmid 19887485?><pub-id pub-id-type="pmid">19887485</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wesseling</surname><given-names>J</given-names></name><name><surname>Tinterri</surname><given-names>C</given-names></name><name><surname>Sapino</surname><given-names>A</given-names></name><name><surname>Zanconati</surname><given-names>F</given-names></name><name><surname>Lutke Holzik</surname><given-names>M</given-names></name><name><surname>Nguyen</surname><given-names>B</given-names></name><name><surname>Deck</surname><given-names>KB</given-names></name><name><surname>Querzoli</surname><given-names>P</given-names></name><name><surname>Perin</surname><given-names>T</given-names></name><name><surname>Giardina</surname><given-names>C</given-names></name><name><surname>Seitz</surname><given-names>G</given-names></name><name><surname>Guinebretiere</surname><given-names>J-M</given-names></name><name><surname>Barone</surname><given-names>J</given-names></name><name><surname>Watanabe</surname><given-names>T</given-names></name><name><surname>De Snoo</surname><given-names>F</given-names></name><name><surname>Stork-Sloots</surname><given-names>L</given-names></name><name><surname>Cusumano</surname><given-names>P</given-names></name></person-group><article-title>Central review of discordant samples for microarray-based ER, PR, and HER2 and local IHC/FISH assessment worldwide from 827 patients [abstract]</article-title><source>J Clin Oncol</source><year>2012</year></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Eklund</surname><given-names>AC</given-names></name><name><surname>Juul</surname><given-names>N</given-names></name><name><surname>Haibe-Kains</surname><given-names>B</given-names></name><name><surname>Workman</surname><given-names>CT</given-names></name><name><surname>Richardson</surname><given-names>AL</given-names></name><name><surname>Szallasi</surname><given-names>Z</given-names></name><name><surname>Swanton</surname><given-names>C</given-names></name></person-group><article-title>Minimising immunohistochemical false negative ER classification using a complementary 23 gene expression signature of ER status</article-title><source>PLoS One</source><year>2010</year><volume>5</volume><fpage>e15031</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0015031</pub-id><?supplied-pmid 21152022?><pub-id pub-id-type="pmid">21152022</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kamalakaran</surname><given-names>S</given-names></name><name><surname>Lezon-Geyda</surname><given-names>K</given-names></name><name><surname>Varadan</surname><given-names>V</given-names></name><name><surname>Banerjee</surname><given-names>N</given-names></name><name><surname>Lannin</surname><given-names>D</given-names></name><name><surname>Rizack</surname><given-names>T</given-names></name><name><surname>Sikov</surname><given-names>W</given-names></name><name><surname>Abu-Khalaf</surname><given-names>M</given-names></name><name><surname>Janevski</surname><given-names>A</given-names></name><name><surname>Harris</surname><given-names>L</given-names></name></person-group><article-title>Evaluation of ER/PR and HER2 status by RNA sequencing in tissue core biopsies from preoperative clinical trial specimens [abstract]</article-title><source>J Clin Oncol</source><year>2011</year></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lusa</surname><given-names>L</given-names></name><name><surname>McShane</surname><given-names>LM</given-names></name><name><surname>Reid</surname><given-names>JF</given-names></name><name><surname>De Cecco</surname><given-names>L</given-names></name><name><surname>Ambrogi</surname><given-names>F</given-names></name><name><surname>Biganzoli</surname><given-names>E</given-names></name><name><surname>Gariboldi</surname><given-names>M</given-names></name><name><surname>Pierotti</surname><given-names>MA</given-names></name></person-group><article-title>Challenges in projecting clustering results across gene expression-profiling datasets</article-title><source>J Natl Cancer Inst</source><year>2007</year><volume>99</volume><fpage>1715</fpage><lpage>1723</lpage><pub-id pub-id-type="doi">10.1093/jnci/djm216</pub-id><?supplied-pmid 18000217?><pub-id pub-id-type="pmid">18000217</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Auer</surname><given-names>PL</given-names></name><name><surname>Doerge</surname><given-names>RW</given-names></name></person-group><article-title>Statistical design and analysis of RNA sequencing data</article-title><source>Genetics</source><year>2010</year><volume>185</volume><fpage>405</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1534/genetics.110.114983</pub-id><?supplied-pmid 20439781?><pub-id pub-id-type="pmid">20439781</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bullard</surname><given-names>JH</given-names></name><name><surname>Purdom</surname><given-names>E</given-names></name><name><surname>Hansen</surname><given-names>KD</given-names></name><name><surname>Dudoit</surname><given-names>S</given-names></name></person-group><article-title>Evaluation of statistical methods for normalization and differential expression in mRNA-Seq experiments</article-title><source>BMC Bioinformatics</source><year>2010</year><volume>11</volume><fpage>94</fpage><pub-id pub-id-type="doi">10.1186/1471-2105-11-94</pub-id><?supplied-pmid 20167110?><pub-id pub-id-type="pmid">20167110</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>W</given-names></name><name><surname>Chung</surname><given-names>LM</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name></person-group><article-title>Bias detection and correction in RNA-Sequencing data</article-title><source>BMC Bioinformatics</source><year>2011</year><volume>12</volume><fpage>290</fpage><pub-id pub-id-type="doi">10.1186/1471-2105-12-290</pub-id><?supplied-pmid 21771300?><pub-id pub-id-type="pmid">21771300</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dillies</surname><given-names>M-A</given-names></name><name><surname>Rau</surname><given-names>A</given-names></name><name><surname>Aubert</surname><given-names>J</given-names></name><name><surname>Hennequet-Antier</surname><given-names>C</given-names></name><name><surname>Jeanmougin</surname><given-names>M</given-names></name><name><surname>Servant</surname><given-names>N</given-names></name><name><surname>Keime</surname><given-names>C</given-names></name><name><surname>Marot</surname><given-names>G</given-names></name><name><surname>Castel</surname><given-names>D</given-names></name><name><surname>Estelle</surname><given-names>J</given-names></name><name><surname>Guernec</surname><given-names>G</given-names></name><name><surname>Jagla</surname><given-names>B</given-names></name><name><surname>Jouneau</surname><given-names>L</given-names></name><name><surname>Lalo&#x000eb;</surname><given-names>D</given-names></name><name><surname>Le Gall</surname><given-names>C</given-names></name><name><surname>Scha&#x000eb;ffer</surname><given-names>B</given-names></name><name><surname>Le Crom</surname><given-names>S</given-names></name><name><surname>Guedj</surname><given-names>M</given-names></name><name><surname>Jaffr&#x000e9;zic</surname><given-names>F</given-names></name><collab>French StatOmique Consortium</collab></person-group><article-title>A comprehensive evaluation of normalization methods for Illumina high-throughput RNA sequencing data analysis</article-title><source>Brief Bioinformatics</source><year>2013</year><volume>14</volume><fpage>671</fpage><lpage>683</lpage><pub-id pub-id-type="doi">10.1093/bib/bbs046</pub-id><?supplied-pmid 22988256?><pub-id pub-id-type="pmid">22988256</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goecks</surname><given-names>J</given-names></name><name><surname>Nekrutenko</surname><given-names>A</given-names></name><name><surname>Taylor</surname><given-names>J</given-names></name><collab>Galaxy Team</collab></person-group><article-title>Galaxy: a comprehensive approach for supporting accessible, reproducible, and transparent computational research in the life sciences</article-title><source>Genome Biol</source><year>2010</year><volume>11</volume><fpage>R86</fpage><pub-id pub-id-type="doi">10.1186/gb-2010-11-8-r86</pub-id><?supplied-pmid 20738864?><pub-id pub-id-type="pmid">20738864</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><mixed-citation publication-type="other"><bold>MAQC Project</bold>. <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/ScienceResearch/BioinformaticsTools/MicroarrayQualityControlProject/">http://www.fda.gov/ScienceResearch/BioinformaticsTools/MicroarrayQualityControlProject/</ext-link></mixed-citation></ref></ref-list></back></article>